{"gene":"FOXA2","run_date":"2026-06-09T23:54:44","timeline":{"discoveries":[{"year":2004,"finding":"Insulin signaling causes nuclear exclusion of Foxa2 (phosphorylation-dependent cytoplasmic localization), inactivating its transcriptional program; a constitutively nuclear Foxa2T156A mutant (cannot be phosphorylated by insulin/PI3K/Akt) activates lipid oxidation, ketogenesis, and glycolysis gene programs in the liver, demonstrating that insulin inhibits Foxa2 by nuclear exclusion.","method":"Adenoviral expression of Foxa2T156A in insulin-resistant mice; nuclear/cytoplasmic fractionation; gene expression analysis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — phosphorylation-site mutagenesis combined with in vivo adenoviral rescue in multiple mouse models, replicated functionally","pmids":["15616563"],"is_preprint":false},{"year":2005,"finding":"Foxa2 is required in hepatocytes for activation of gluconeogenic gene programs during fasting; it acts as a chromatin-level co-activator enabling recruitment of CREB and glucocorticoid receptor (GR) to their target sites, integrating cAMP and glucocorticoid hormone signals.","method":"Cell-type-specific Foxa2 gene ablation; chromatin immunoprecipitation (ChIP) for CREB and GR occupancy at gluconeogenic promoters","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with defined molecular phenotype plus ChIP demonstrating impaired co-factor recruitment, single lab but multiple orthogonal methods","pmids":["16098831"],"is_preprint":false},{"year":2013,"finding":"Glucagon induces acetylation of Foxa2 at the conserved residue Lys259; the co-activator p300 acetylates Foxa2 and SirT1 deacetylates it; acetylation-mimicking mutation K259Q increases Foxa2 transcriptional activity on fatty acid oxidation and ketogenesis genes, while K259R reduces it, establishing glucagon-induced acetylation as a positive regulatory PTM.","method":"Site-directed mutagenesis (K259Q/K259R); HDAC inhibitor treatment; co-immunoprecipitation of p300 and SirT1 with Foxa2; adenoviral expression in mice; gene expression analysis","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — in vitro mutagenesis, co-IP of writer/eraser, in vivo adenoviral rescue; single lab but multiple orthogonal methods","pmids":["23416070"],"is_preprint":false},{"year":2014,"finding":"SIRT1 physically interacts with FOXA2, deacetylates it in a nutrient-dependent manner, and targets it for proteasomal degradation; during starvation, the SIRT1-FOXA2 interaction is reduced, FOXA2 acetylation increases, and FOXA2 is stabilized, enabling its transcriptional program (G6pase, CPT1a) in liver.","method":"LC-MS/MS identification of five acetylated FOXA2 residues; co-IP of SIRT1 with FOXA2; siRNA knockdown of UBC9; promoter-reporter assays; murine starvation model","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — mass spectrometry identification of acetylation sites, co-IP, functional mutagenesis, and in vivo starvation experiments; single lab, multiple orthogonal methods","pmids":["24875183"],"is_preprint":false},{"year":2013,"finding":"SIRT1 forms a protein complex with FOXA2 on the Pdx1 gene promoter; SIRT1 deacetylates FOXA2 and positively regulates Pdx1 transcription in pancreatic beta cells; pancreas-specific SIRT1 disruption diminishes PDX1 expression and impairs islet development.","method":"Co-immunoprecipitation; ChIP on Pdx1 promoter; pancreas-specific Sirt1 knockout mice","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP and ChIP in same study, single lab","pmids":["24163589"],"is_preprint":false},{"year":2011,"finding":"IKKα (downstream of TNFα) phosphorylates FOXA2 at Ser107/Ser111, suppressing FOXA2 transactivation activity, reducing NUMB expression, and consequently activating NOTCH1 signaling to promote hepatocellular carcinoma cell proliferation; this defines a TNFα/IKKα/FOXA2/NUMB/NOTCH1 pathway.","method":"Co-immunoprecipitation of IKKα with FOXA2; phospho-specific antibody staining; transactivation reporter assays; knockdown experiments in cell lines and tumor tissue analysis","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Moderate — direct phosphorylation by identified kinase, co-IP, transactivation assay, in vivo tumor correlation; single lab, multiple orthogonal methods","pmids":["22196886"],"is_preprint":false},{"year":2012,"finding":"FOXA2 is sumoylated at Lys6 by SUMO-1; preventing sumoylation (K6R mutation) destabilizes FOXA2 protein (promotes proteasomal degradation) without affecting nuclear localization; PIAS1 SUMO ligase increases FOXA2 levels and transcriptional activity on Pdx-1 enhancer; UBC9 knockdown reduces FOXA2 protein levels.","method":"Site-directed mutagenesis (K6R); SUMO-1 in-frame fusion rescue; siRNA knockdown of UBC9; co-immunoprecipitation with PIAS1; promoter-reporter assays in INS-1E, HepG2, and other cell lines","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — mutagenesis of SUMO acceptor site, identification of E2/E3 enzymes, rescue by direct fusion; single lab but multiple orthogonal methods","pmids":["23118920"],"is_preprint":false},{"year":2004,"finding":"Foxa2 is required in pancreatic beta cells for expression of both Kir6.2 and SUR1 (ATP-sensitive K+ channel subunits) and Hadhsc; Foxa2 directly binds and activates the Hadhsc promoter; loss of Foxa2 causes excessive insulin release to amino acids and complete loss of glucose-stimulated insulin secretion.","method":"Conditional beta-cell-specific Foxa2 deletion; isolated islet functional assays; RNA in situ hybridization; chromatin immunoprecipitation; cotransfection reporter assays","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — conditional KO mouse with functional islet assays plus ChIP and cotransfection to confirm direct Hadhsc target; multiple orthogonal methods","pmids":["15314688"],"is_preprint":false},{"year":2007,"finding":"Inducible deletion of Foxa2 in mature beta cells increases the docked insulin granule pool and first-phase glucose-stimulated insulin secretion; Foxa2 regulates expression of multiple genes in vesicular trafficking and membrane targeting, and its loss alters intracellular Ca2+ oscillations and elevates cAMP.","method":"Inducible Foxa2 gene ablation (Pdx1-CreERT2); electron microscopy of granule pools; Ca2+ oscillation measurements; cAMP measurement; expression profiling","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 2 / Moderate — inducible conditional KO with multiple cellular phenotype readouts; single lab, multiple orthogonal methods","pmids":["17908556"],"is_preprint":false},{"year":2010,"finding":"Simultaneous inducible ablation of Foxa1 and Foxa2 in mature beta cells impairs glucose homeostasis and insulin secretion more severely than loss of Foxa2 alone; both factors directly regulate ChREBP (Mlxipl) expression in fetal endocrine pancreas and adult islets.","method":"Inducible double conditional KO; isolated islet secretion assays; Ca2+ oscillation measurements; ChIP for Foxa1/Foxa2 at ChREBP promoter; expression profiling","journal":"Molecular endocrinology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — inducible double KO with functional assays and ChIP confirmation of direct target; single lab, multiple orthogonal methods","pmids":["20534694"],"is_preprint":false},{"year":2015,"finding":"Insm1, Neurod1, and Foxa2 physically interact and co-occupy regulatory sequences in mature pancreatic beta-cell genomes; combinatorial binding of all three factors explains a significant fraction of gene expression changes needed to maintain beta-cell maturity.","method":"Co-immunoprecipitation of Insm1 with Neurod1 and Foxa2; ChIP-seq for all three factors; Insm1 beta-cell-specific ablation; gene expression profiling","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — co-IP plus ChIP-seq plus conditional KO all in the same study; multiple orthogonal methods","pmids":["25828096"],"is_preprint":false},{"year":2017,"finding":"Crystal structure (2.8 Å) of the FOXA2 DNA-binding domain bound to the forkhead consensus site (GTAAACA) shows helix H3 and wing 1 mediate DNA recognition via the canonical winged-helix fold, with more major-groove and fewer minor-groove contacts than FOXA3; wing 2 is required for optimal binding (ITC).","method":"X-ray crystallography (2.8 Å co-crystal); isothermal titration calorimetry (ITC) for wing 2 deletion","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure with functional validation by ITC; single study but rigorous structural method","pmids":["28644006"],"is_preprint":false},{"year":2012,"finding":"Foxa2 and the histone variant H2A.Z cooperate to mediate nucleosome depletion at endodermal gene loci during ES cell differentiation into endoderm; nucleosome depletion is dependent on Nap1l1-coupled SWI/SNF and INO80 chromatin remodeling complexes; DNA methylation promotes nucleosome occupation and suppresses gene expression.","method":"MNase-seq for nucleosome occupancy; Foxa2 knockdown during ES differentiation; ChIP-seq; pharmacological inhibition of SWI/SNF and INO80","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide nucleosome mapping plus KD with multiple chromatin remodeling complex dependencies identified; multiple orthogonal methods in a single study","pmids":["23260146"],"is_preprint":false},{"year":2019,"finding":"FOXA2 is required as a pioneer factor for chromatin opening and H3K4me1 deposition (enhancer priming) during human pancreatic specification; FOXA2 KO in hPSCs reduces pancreatic progenitor numbers and impairs GATA6 recruitment to pancreatic enhancers.","method":"CRISPR/Cas9 FOXA2 knockout in hPSCs; ATAC-seq; ChIP-seq for H3K4me1 and GATA6; directed pancreatic differentiation","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — CRISPR KO plus ATAC-seq and ChIP-seq in the same study; multiple orthogonal methods, single lab","pmids":["31291575"],"is_preprint":false},{"year":2019,"finding":"Pioneer factor Foxa2 binding site selection is directed by epigenetic priming (low levels of active chromatin marks in ESCs); Foxa2 binding alone is not sufficient for chromatin opening—increased accessibility requires synergistic co-binding with other endoderm transcription factors.","method":"ATAC-seq; ChIP-seq for active chromatin marks; ectopic Foxa2 expression in ESCs followed by genome-wide binding analysis","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genome-wide chromatin accessibility and binding studies with ectopic expression and endogenous conditions; single lab, multiple orthogonal methods","pmids":["31350899"],"is_preprint":false},{"year":2022,"finding":"TET1 dioxygenase physically interacts with FOXA2 in endodermal lineage intermediates; TET depletion reduces FOXA2 binding at pancreatic progenitor enhancers; TET1-dependent DNA demethylation is required for FOXA2-associated chromatin remodeling during beta-cell differentiation.","method":"TET1/2/3 triple knockout hESCs; WGBS; ATAC-seq; ChIP-seq; co-immunoprecipitation of TET1 with FOXA2; directed beta-cell differentiation","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — co-IP identifying physical interaction, genome-wide methylome/accessibility analyses in KO context; multiple orthogonal methods, single lab","pmids":["35798741"],"is_preprint":false},{"year":2005,"finding":"Foxa1 and Foxa2 physically interact with the DNA-binding domain of the androgen receptor (AR); both Foxa proteins can be recruited to AR binding sites in the absence of Foxa consensus sequences, and AR is recruited to Foxa binding sites in the absence of an AR binding site, indicating mutual recruitment; Foxa2 (but not Foxa1) is expressed in the epididymis and binds the mE-RABP promoter.","method":"GST pull-down assay; gel-shift (EMSA); chromatin immunoprecipitation (ChIP); co-transfection reporter assays","journal":"Annals of the New York Academy of Sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — GST pulldown plus ChIP plus EMSA in one study; single lab, multiple methods","pmids":["16467259"],"is_preprint":false},{"year":2009,"finding":"Foxa1 and Foxa2 are required for normal bile duct development; in their absence, glucocorticoid receptor fails to bind the IL-6 promoter, causing enhanced IL-6 expression and cholangiocyte hyperproliferation; Foxa1/2 thus function as terminators of bile duct expansion by enabling GR-mediated repression of IL-6.","method":"Conditional double Foxa1/2 liver-specific knockout; ChIP for glucocorticoid receptor at IL-6 promoter; gene expression analysis","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Moderate — conditional KO with defined molecular mechanism (GR ChIP) plus IL-6 expression phenotype; single lab, multiple methods","pmids":["19436110"],"is_preprint":false},{"year":2009,"finding":"Foxa1/2 chromatin immunoprecipitation indicates that Nkx2.2 and tyrosine hydroxylase (TH) genes are direct targets in mesodiencephalic dopaminergic cells; Foxa1 and Foxa2 positively regulate Lmx1a and Lmx1b and inhibit Nkx2.2, and function cooperatively with Lmx1a/Lmx1b in a feedforward loop for DA neuron differentiation.","method":"Conditional Foxa1/2 knockout mice; chromatin immunoprecipitation for Foxa2 at Nkx2.2 and TH loci; gene expression analysis","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO combined with ChIP for direct targets; single lab","pmids":["19607821"],"is_preprint":false},{"year":2010,"finding":"Foxa2 directly binds Gli2 genomic regions (ChIP) and represses Gli2 transcription, thereby attenuating Shh signaling in ventral midbrain progenitors; Foxa1 and Foxa2 both positively and negatively regulate Shh pathway components to specify ventral midbrain progenitor identity.","method":"Conditional Foxa2 knockout in midbrain (Wnt1-Cre); gain-of-function studies; ChIP for Foxa2 at Gli2 locus; gene expression analysis","journal":"Mechanisms of development","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP confirming direct Gli2 binding plus in vivo conditional KO/GOF; single lab","pmids":["21093585"],"is_preprint":false},{"year":2014,"finding":"Foxa2 acts as a co-activator of Nurr1-induced dopaminergic (DA) gene expression by displacing the Nurr1-CoREST repressor complex; in the presence of Foxa2, Nurr1 forms an activator complex with Foxa2 instead, reducing CoREST/Hdac1 enrichment at DA gene promoters and increasing H3 acetylation (open chromatin) at those promoters.","method":"Co-immunoprecipitation of Nurr1 with CoREST and Foxa2; ChIP for CoREST, Hdac1 and H3Ac at DA gene promoters; reporter assays; neural precursor cell differentiation","journal":"Development","confidence":"High","confidence_rationale":"Tier 2 / Moderate — co-IP defining complex composition, ChIP showing histone modification changes, promoter reporter assays; single lab, multiple orthogonal methods","pmids":["24496614"],"is_preprint":false},{"year":2009,"finding":"FOXA2 and HNF4α co-occupy thousands of genomic regulatory elements in hepatocytes; co-immunoprecipitation confirmed a physical interaction between HNF4α and GABP at transcription start sites, and HNF4α/FOXA2 frequently co-occupy distal elements together with USF2.","method":"ChIP-seq for FOXA2, HNF4α, and GABP; co-immunoprecipitation of HNF4α and GABP","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — ChIP-seq genome-wide binding plus co-IP; single lab, co-IP only for HNF4α-GABP interaction, not FOXA2 complex directly","pmids":["19822575"],"is_preprint":false},{"year":2009,"finding":"Foxa2 regulates polarity and epithelialization of endoderm cells; Foxa2-mutant endodermal cells fail to maintain apical-basal polarity and cannot establish proper cellular junctions, preventing integration into the endoderm epithelium, indicating Foxa2 promotes an epithelial fate and suppresses a mesenchymal fate.","method":"Foxa2 conditional knockout; immunohistochemistry for polarity/junction markers; time-lapse confocal imaging","journal":"Development","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with live imaging and junction marker analysis; single lab, multiple methods","pmids":["19234065"],"is_preprint":false},{"year":2012,"finding":"Foxa1/2 deficiency in the liver abolishes the sexual dimorphism of hepatocellular carcinoma; Foxa1/2 are required for co-regulation of target genes by either ERα (in females) or the androgen receptor (AR) (in males) during hepatocarcinogenesis; FOXA2 binding site SNPs reduce co-occupancy of FOXA2 and ERα in human liver.","method":"Conditional double Foxa1/2 knockout after DEN-induced hepatocarcinogenesis; ChIP-seq for Foxa1/2, ERα, and AR; SNP analysis of FOXA2 binding sites","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with in vivo carcinogenesis model plus ChIP-seq for multiple TFs; multiple orthogonal methods, single lab","pmids":["22265403"],"is_preprint":false},{"year":2018,"finding":"FOXA2 physically interacts with FXR (farnesoid X receptor/bile acid receptor) in hepatocytes; glucagon-activated FOXA2 inhibits FXR's ability to induce SHP (an anti-gluconeogenic nuclear receptor) through this protein-protein interaction; this represents a second arm of FXR regulation in fasting hepatic gluconeogenesis.","method":"In vitro protein-protein interaction assays (pull-down); cistromic (ChIP-seq) analysis; Foxa2 knockdown in primary hepatocytes; transactivation assays; site-directed mutagenesis of FXR","journal":"Journal of hepatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro binding assay plus ChIP and functional reporter assays; single lab","pmids":["29981427"],"is_preprint":false},{"year":2013,"finding":"Neurogenin3 (Neurog3) can autoactivate its own expression; Foxa2 cooperates synergistically with Neurogenin3 to amplify this autoregulation in vitro; Foxa2 colocalizes with Neurogenin3 in pancreatic progenitors in vivo; Foxa2 RNAi attenuates Neurogenin3-dependent activation of the endocrine developmental program.","method":"ChIP for Neurogenin3 at its own upstream region; reporter assays with Foxa2 co-expression; RNA interference of Foxa2 in mPAC cells; immunofluorescence co-localization in embryonic pancreas","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus reporter assays plus RNAi knockdown; single lab, multiple orthogonal methods","pmids":["23471965"],"is_preprint":false},{"year":2009,"finding":"Foxa2 regulates hepatic gene networks in a physiological-state-dependent manner by interacting with different transcription factor partners depending on the presence or absence of cholic acid; distinct feedforward regulatory loops control Foxa2-dependent targets under different physiological conditions.","method":"Foxa2 liver-specific knockout; functional genomics (expression profiling under cholic acid diet); co-immunoprecipitation with partner transcription factors","journal":"Physiological genomics","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — conditional KO plus expression profiling; co-IP evidence for partner interactions; single lab","pmids":["19417011"],"is_preprint":false},{"year":2012,"finding":"β-catenin signaling directly regulates Foxa2 expression in uterine epithelia; Foxa2 knockdown in uterine epithelial cells causes defects in cell cycle regulation, suggesting a role for Foxa2 in controlling cell proliferation downstream of β-catenin.","method":"Conditional β-catenin ablation/activation in uterus; ChIP for β-catenin at Foxa2 locus; siRNA knockdown of Foxa2; cell cycle analysis","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP establishing direct regulation plus KO/siRNA with functional readout; single lab","pmids":["22945641"],"is_preprint":false},{"year":2012,"finding":"GATA6 and FOXA2 directly bind the Wnt6 promoter and cooperate to activate Wnt6 gene expression during extraembryonic endoderm formation, thereby activating the canonical WNT-β-catenin pathway.","method":"Chromatin immunoprecipitation; reporter assay with GATA6/FOXA2 overexpression; F9 teratocarcinoma cell differentiation model","journal":"Stem cells and development","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP confirming direct promoter binding plus reporter assays; single lab","pmids":["22607194"],"is_preprint":false},{"year":2019,"finding":"FOXA2 controls distinct cis-regulatory networks in well- vs. poorly-differentiated pancreatic ductal adenocarcinoma cells via grade-specific partnerships with different co-binding transcription factors, despite being expressed in both cell types; FOXA2 genomic distribution and regulated gene programs differ extensively by differentiation grade.","method":"ChIP-seq for FOXA2 in multiple PDAC cell lines; ATAC-seq; transcriptome analysis; FOXA2 knockdown","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP-seq and ATAC-seq across multiple cell lines with KD validation; single lab, multiple orthogonal methods","pmids":["31531882"],"is_preprint":false},{"year":2020,"finding":"PHF8 histone demethylase transcriptionally upregulates FOXA2 by demethylating repressive histone marks on the FOXA2 promoter; PHF8 is required for neuroendocrine prostate cancer (NEPC) development and acts upstream of FOXA2 in the NEPC transcriptional program.","method":"PHF8 knockout in TRAMP mice; ChIP for repressive histone marks at FOXA2 promoter; gene expression analysis; xenograft models","journal":"The Journal of pathology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo KO model with ChIP-based mechanism; single lab","pmids":["33009820"],"is_preprint":false},{"year":2022,"finding":"FOXA2 drives prostate cancer adeno-to-neuroendocrine lineage transition; FOXA2 expression is induced by androgen deprivation; FOXA2 knockdown reverses the transition; FOXA2 directly regulates the KIT pathway, which is specifically activated in neuroendocrine prostate cancer.","method":"Single-cell multiomics (scRNA-seq + ATAC-seq) in genetically engineered mouse models; FOXA2 knockdown; KIT pathway inhibition experiments; human NEPC tumor analysis","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — single-cell multiomics plus KD rescue plus pharmacological inhibition; multiple orthogonal methods","pmids":["36332622"],"is_preprint":false},{"year":2024,"finding":"FOXA2 acts as a pioneer factor that binds distinct classes of developmental enhancers in AR-independent prostate cancer subtypes in an LSD1-dependent manner; FOXA2 collaborates with JUN at chromatin to reprogram AP-1 transcriptional activity, driving cell state transitions to multiple cancer lineages.","method":"ChIP-seq for FOXA2 and JUN; ATAC-seq; LSD1 inhibition; FOXA2 overexpression in multiple PCa cell lines","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP-seq and ATAC-seq establishing co-occupancy plus LSD1-dependence experiments; single lab, multiple orthogonal methods","pmids":["38851846"],"is_preprint":false},{"year":2021,"finding":"In cardiomyocytes, FOXA2 directly represses RIPK3 gene transcription by binding its promoter region; loss of FOXA2 (through HDAC7-dependent suppression) increases RIPK3-dependent necroptosis; this pathway is governed by the CNEACR/HDAC7/Foxa2/RIPK3 axis.","method":"ChIP showing FOXA2 occupancy at RIPK3 promoter; FOXA2 overexpression/knockdown in cardiomyocytes; H/R injury model; HDAC7 nuclear/cytoplasmic fractionation","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP at RIPK3 promoter plus functional KD/OE assays; single lab","pmids":["34588633"],"is_preprint":false},{"year":2014,"finding":"TXNIP increases FoxA2 expression, which then binds the proximal FoxA2 site in the IAPP promoter to activate IAPP transcription; TXNIP also downregulates miR-124a, relieving miR-124a-mediated suppression of FoxA2; thus TXNIP controls IAPP expression via a TXNIP/miR-124a/FoxA2/IAPP cascade.","method":"Chromatin immunoprecipitation of FoxA2 at IAPP promoter; luciferase reporter assays; miR-124a overexpression/knockdown; beta-cell-specific Txnip knockout mice","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP confirming FoxA2 occupancy at IAPP promoter, miRNA manipulation, and in vivo KO; single lab","pmids":["24627476"],"is_preprint":false},{"year":2011,"finding":"Foxa2 binds specific DNA sequences in the cIAP1 promoter and activates cIAP1 transcription; Foxa2 overexpression decreases hepatocyte apoptosis while siRNA silencing increases it, suggesting Foxa2 modulates hepatic apoptosis through the cIAP1 pathway.","method":"EMSA and gel supershift assay; ChIP for Foxa2 at cIAP1 promoter; deletion reporter assays; siRNA knockdown; Foxa2 overexpression in HepG2 cells","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EMSA plus ChIP plus reporter deletion analysis confirm direct binding; single lab","pmids":["23275033"],"is_preprint":false},{"year":2013,"finding":"Hippo kinases Mst1/2 stabilize and phosphorylate Foxa2 in respiratory epithelial cells; Mst1/2 conditional knockout mice develop perinatal respiratory failure with defects in pneumocyte differentiation and surfactant protein expression attributed to reduced/destabilized Foxa2, independently of YAP.","method":"Mst1/2 conditional knockout mice; co-immunoprecipitation/phosphorylation assay of Foxa2 by Mst1/2; histological and molecular analysis of surfactant gene expression","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO phenotype plus biochemical demonstration of Foxa2 phosphorylation/stabilization by Mst1/2; single lab","pmids":["23620511"],"is_preprint":false},{"year":2022,"finding":"FOXA2 broadly controls gene expression programs in endometrial epithelial cells through modification of enhancer activity (not only direct promoter binding); simultaneous conditional inactivation of Foxa2 and Pten in endometrial epithelium causes lethal endometrial cancers with complete penetrance, establishing epistatic synergism between Foxa2 tumor suppressor and PI3K signaling.","method":"Conditional Foxa2 and Pten single/double knockout mice; RNA-seq; ChIP-seq (cistrome); organoid models; cell line functional assays","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis by conditional double KO in vivo plus cistrome analysis; multiple orthogonal methods, single lab","pmids":["35703180"],"is_preprint":false},{"year":2017,"finding":"A de novo FOXA2 mutation (p.S169P) within the DNA-binding domain impairs FOXA2 transcriptional reporter activity and reduces protein levels, causing congenital hyperinsulinism and hypopituitarism with endoderm-derived organ abnormalities in humans.","method":"Whole-exome sequencing; transient transfection reporter assays in HEK293T cells with WT vs. mutant FOXA2; western blot for protein levels","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — functional validation of mutation in cell lines; single study, limited to transfection reporter","pmids":["28973288"],"is_preprint":false},{"year":2010,"finding":"Foxa2 expression in respiratory epithelial cells suppresses Th2 cell-mediated pulmonary inflammation; deletion of Foxa2 induces expression of IL-13, IL-4, eotaxins, Il33, and Ccl20, recruiting myeloid dendritic cells and Th2 cells; pulmonary inflammation was abrogated by anti-IL-4Rα antibody treatment.","method":"Respiratory epithelial cell-specific Foxa2 conditional knockout; cytokine/chemokine gene expression; flow cytometry for immune cell infiltrates; anti-IL-4Rα antibody rescue","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with defined cytokine program and antibody rescue; single lab, multiple methods","pmids":["20483781"],"is_preprint":false},{"year":2015,"finding":"Lhx1, Otx2, and Foxa2 form a protein complex with the chromatin-looping protein Ldb1 in anterior mesendoderm; this complex was characterized by proteomic co-immunoprecipitation and co-regulates development of anterior mesendoderm, node, and midline populations.","method":"Co-immunoprecipitation/proteomics; ChIP-seq for Lhx1, Otx2, Foxa2; conditional Lhx1 inactivation","journal":"Genes & development","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — proteomic co-IP identifying complex plus ChIP-seq; single lab","pmids":["26494787"],"is_preprint":false},{"year":2023,"finding":"TRIM36, an E3 ubiquitin ligase, directly interacts with FOXA2 and induces its K48-linked polyubiquitination, leading to FOXA2 proteasomal degradation; FOXA2 positively regulates NRF2 pathway activation and GPX4 levels in colorectal cancer cells to suppress ferroptosis.","method":"Co-immunoprecipitation of TRIM36 with FOXA2; ubiquitination assays (K48-linkage); FOXA2 depletion by siRNA/CRISPR; NRF2/GPX4 expression analysis","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus ubiquitination assay identifying writer/linkage; single lab","pmids":["37875418"],"is_preprint":false},{"year":2010,"finding":"The Siah2 ubiquitin ligase controls HIF-1α availability; HIF-1α forms a transcriptional complex with FoxA2, and this complex drives expression of neuroendocrine prostate cancer target genes (Hes6, Sox9, Jmjd1a); this Siah2-HIF-1α/FoxA2 axis regulates neuroendocrine tumor formation.","method":"Co-immunoprecipitation of HIF-1α with FoxA2; gene expression analysis; Siah2 inhibition experiments (review/perspective summarizing experimental findings from cited primary work)","journal":"Oncotarget","confidence":"Low","confidence_rationale":"Tier 3 / Weak — review/perspective summarizing co-IP data from primary studies; not a primary experimental paper","pmids":["21037926"],"is_preprint":false},{"year":2014,"finding":"Foxa1 and Foxa2 control glucagon gene expression through the G2 element in pancreatic alpha cells; Foxa2 (but not Foxa1) regulates MafB, Pou3f4, Pcsk2, Nkx2.2, Kir6.2, and Sur1 gene expression; combined Foxa1/Foxa2 loss affects glucagon secretion; Foxa2 directly binds the promoters of Nkx2.2, Kir6.2, Sur1, Gipr, Isl1, and Pou3f4 genes.","method":"siRNA knockdown of Foxa1/Foxa2 in primary rat alpha cells and alpha-cell lines; ChIP for Foxa2 at target gene promoters; glucagon secretion assays","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP confirming direct binding at multiple promoters plus siRNA functional assays; single lab","pmids":["25057789"],"is_preprint":false}],"current_model":"FOXA2 (HNF3B) is a winged-helix pioneer transcription factor whose nuclear activity is regulated by multiple post-translational modifications—including insulin/PI3K/Akt-mediated phosphorylation at Thr156 causing cytoplasmic sequestration, glucagon-induced p300-mediated acetylation at Lys259 promoting activity, SIRT1-mediated deacetylation targeting it for proteasomal degradation, SUMO-1 modification at Lys6 stabilizing it, IKKα-mediated phosphorylation at Ser107/Ser111 suppressing transactivation, and TRIM36-mediated K48-polyubiquitination causing degradation; in the liver it acts as a chromatin-level co-activator that enables CREB and glucocorticoid receptor recruitment to gluconeogenic gene promoters during fasting, activates fatty acid oxidation and ketogenesis programs, and cooperates with nuclear receptors (FXR, GR) and partner transcription factors (HNF4α, GATA6); in the pancreas it functions as a pioneer factor required for enhancer priming (H3K4me1 deposition), chromatin opening, and recruitment of GATA6 and other lineage TFs, directly activating Kir6.2, SUR1, Hadhsc, ChREBP, and Pdx1 to control insulin secretion and beta-cell identity; in the brain it cooperates with Nurr1 by displacing the Nurr1-CoREST-HDAC1 repressor complex to drive dopaminergic gene expression; and its crystal structure reveals that DNA recognition occurs primarily through helix H3 and wing 1 of the canonical winged-helix fold."},"narrative":{"mechanistic_narrative":"FOXA2 (HNF3B) is a winged-helix pioneer transcription factor that opens chromatin at developmental and metabolic enhancers and licenses other transcription factors for DNA binding, thereby controlling endoderm-derived lineage specification and tissue-specific gene programs [PMID:31291575, PMID:23260146]. Its DNA-binding domain engages the forkhead consensus (GTAAACA) through helix H3 and wing 1 of the canonical winged-helix fold, with wing 2 required for optimal binding [PMID:28644006]. As a pioneer factor it cooperates with the histone variant H2A.Z and Nap1l1-coupled SWI/SNF and INO80 remodelers to deplete nucleosomes at endodermal loci, and during human pancreatic specification it deposits H3K4me1 at enhancers and enables GATA6 recruitment; its binding-site selection is guided by epigenetic priming and TET1-dependent DNA demethylation, and accessibility gains require synergistic co-binding with partner endoderm factors [PMID:23260146, PMID:31291575, PMID:31350899, PMID:35798741]. In the pancreas FOXA2 is required for beta-cell identity and glucose-stimulated insulin secretion, directly activating Kir6.2, SUR1, Hadhsc, and ChREBP and cooperating with Insm1, Neurod1, and Neurogenin3 [PMID:15314688, PMID:17908556, PMID:20534694, PMID:25828096, PMID:23471965]. In the liver it acts as a chromatin-level co-activator that enables CREB and glucocorticoid-receptor recruitment to gluconeogenic promoters during fasting and drives fatty-acid oxidation and ketogenesis, cooperating with HNF4α and the bile-acid receptor FXR [PMID:16098831, PMID:19822575, PMID:29981427]. In the brain it converts the Nurr1-CoREST-HDAC1 repressor complex into an activator complex to drive dopaminergic gene expression [PMID:24496614]. FOXA2 nuclear activity and stability are tuned by an extensive set of post-translational modifications: insulin/PI3K/Akt phosphorylation at Thr156 drives cytoplasmic sequestration, glucagon-induced p300 acetylation at Lys259 activates it while SIRT1 deacetylation targets it for proteasomal degradation, SUMO-1 modification at Lys6 stabilizes it, IKKα phosphorylation at Ser107/Ser111 suppresses transactivation, and TRIM36-mediated K48-polyubiquitination drives its degradation [PMID:15616563, PMID:23416070, PMID:24875183, PMID:23118920, PMID:22196886, PMID:37875418]. It also operates as a context-dependent tumor suppressor or lineage-reprogramming driver, synergizing epistatically with PI3K/PTEN signaling in endometrium and driving AR-independent adeno-to-neuroendocrine transitions in prostate cancer via JUN/LSD1-dependent enhancer reprogramming [PMID:35703180, PMID:36332622, PMID:38851846]. A de novo p.S169P mutation in the DNA-binding domain causes congenital hyperinsulinism and hypopituitarism with endoderm-organ abnormalities [PMID:28973288].","teleology":[{"year":2004,"claim":"Established that insulin signaling inactivates FOXA2 not by altering its expression but by spatial regulation, defining a phosphorylation-controlled nucleocytoplasmic switch over its metabolic program.","evidence":"Adenoviral Foxa2T156A phospho-mutant expression with nuclear/cytoplasmic fractionation in insulin-resistant mice","pmids":["15616563"],"confidence":"High","gaps":["Identity of the precise Akt-FOXA2 cytoplasmic-retention machinery not resolved","Does not address PTM crosstalk with later-discovered acetylation/sumoylation"]},{"year":2004,"claim":"Showed FOXA2 is required for beta-cell secretory competence by directly controlling K-ATP channel subunits and a metabolic target, linking the factor to insulin-secretion physiology.","evidence":"Beta-cell-specific conditional Foxa2 knockout with islet functional assays, ChIP, and reporter assays on Hadhsc","pmids":["15314688"],"confidence":"High","gaps":["Direct vs. indirect regulation of Kir6.2/SUR1 not fully separated","Pioneer-factor role at these loci not yet defined"]},{"year":2005,"claim":"Defined FOXA2 as a chromatin-level co-activator that integrates cAMP and glucocorticoid signals by enabling CREB and GR occupancy at gluconeogenic promoters during fasting.","evidence":"Hepatocyte conditional Foxa2 ablation with ChIP for CREB and GR at gluconeogenic promoters","pmids":["16098831"],"confidence":"High","gaps":["Whether FOXA2 directly opens chromatin or recruits co-factors not mechanistically separated here","Stoichiometry of FOXA2/CREB/GR complex unknown"]},{"year":2005,"claim":"Demonstrated mutual recruitment between FOXA2 and the androgen receptor, an early indication that FOXA proteins direct nuclear-receptor cistromes.","evidence":"GST pull-down, EMSA, ChIP, and reporter assays; epididymis mE-RABP promoter","pmids":["16467259"],"confidence":"Medium","gaps":["Structural basis of FOXA2-AR DBD interaction not resolved","Genome-wide generality not established in this study"]},{"year":2009,"claim":"Extended FOXA2 partnerships to hepatic master regulators, showing genome-wide co-occupancy with HNF4α at thousands of regulatory elements.","evidence":"ChIP-seq for FOXA2, HNF4α, GABP plus co-IP","pmids":["19822575"],"confidence":"Medium","gaps":["Direct FOXA2-HNF4α physical interaction not demonstrated by reciprocal co-IP","Functional consequence of co-occupancy not tested by perturbation"]},{"year":2009,"claim":"Defined FOXA1/2 as developmental terminators of bile-duct expansion through enabling GR-mediated repression of IL-6.","evidence":"Liver-specific Foxa1/2 double conditional KO with GR ChIP at IL-6 promoter","pmids":["19436110"],"confidence":"High","gaps":["Direct FOXA-GR interaction at IL-6 not biochemically shown","Redundancy between FOXA1 and FOXA2 not separated"]},{"year":2009,"claim":"Placed FOXA1/2 in midbrain dopaminergic specification as direct regulators of TH, Nkx2.2, and Shh-pathway feedforward loops.","evidence":"Conditional Foxa1/2 KO with ChIP for Foxa2 at Nkx2.2/TH and Gli2 loci","pmids":["19607821","21093585"],"confidence":"Medium","gaps":["Direct vs. indirect repression of Gli2/Nkx2.2 not fully dissected","Co-factor requirements for repression unknown"]},{"year":2009,"claim":"Revealed FOXA2 controls endoderm epithelialization and polarity, linking the factor to morphogenesis beyond gene transcription.","evidence":"Foxa2 conditional KO with polarity/junction immunostaining and time-lapse imaging","pmids":["19234065"],"confidence":"Medium","gaps":["Transcriptional targets driving polarity not identified","Cell-autonomy not fully resolved"]},{"year":2011,"claim":"Identified a kinase that suppresses FOXA2 transactivation, connecting inflammatory TNFα/IKKα signaling to the FOXA2/NUMB/NOTCH1 axis in liver cancer.","evidence":"IKKα-FOXA2 co-IP, phospho-Ser107/111 detection, transactivation reporters, knockdown and tumor analysis","pmids":["22196886"],"confidence":"High","gaps":["Direct kinase-substrate phosphorylation in vitro not the sole readout","Effect on FOXA2 DNA binding vs. co-factor recruitment not separated"]},{"year":2012,"claim":"Defined the pioneer mechanism: FOXA2 with H2A.Z drives nucleosome depletion at endodermal loci via Nap1l1-coupled SWI/SNF and INO80, with DNA methylation opposing accessibility.","evidence":"MNase-seq, ChIP-seq, Foxa2 knockdown during ESC-to-endoderm differentiation, remodeler inhibition","pmids":["23260146"],"confidence":"High","gaps":["Direct FOXA2-remodeler contacts not biochemically defined","Order of H2A.Z deposition vs. FOXA2 binding unresolved"]},{"year":2012,"claim":"Showed FOXA2 stability is positively controlled by SUMO-1 modification at Lys6, adding a degradation-protective PTM layer.","evidence":"K6R mutagenesis, SUMO-1 fusion rescue, UBC9 knockdown, PIAS1 co-IP, reporter assays across cell lines","pmids":["23118920"],"confidence":"High","gaps":["Physiological signal driving sumoylation not identified","Crosstalk with ubiquitination machinery not mapped"]},{"year":2013,"claim":"Established glucagon-induced Lys259 acetylation as a positive activity switch with p300 as writer and SIRT1 as eraser, opposing the insulin-driven inhibition.","evidence":"K259Q/K259R mutagenesis, HDAC inhibition, p300/SirT1 co-IP, adenoviral in vivo expression","pmids":["23416070"],"confidence":"High","gaps":["How acetylation alters FOXA2 chromatin engagement not resolved","Integration with Thr156 phosphorylation not mechanistically linked"]},{"year":2014,"claim":"Clarified SIRT1 as a nutrient-responsive regulator that deacetylates FOXA2 and targets it for proteasomal turnover, coupling fasting signals to FOXA2 stability.","evidence":"LC-MS/MS acetyl-site mapping, SIRT1-FOXA2 co-IP, reporter assays, murine starvation model","pmids":["24875183"],"confidence":"High","gaps":["E3 ligase coupling SIRT1 deacetylation to degradation not identified here","Apparent context-dependence vs. SIRT1's positive role on Pdx1 unresolved"]},{"year":2013,"claim":"Showed SIRT1-FOXA2 cooperation can also be activating, forming a complex on the Pdx1 promoter required for islet development.","evidence":"Co-IP, ChIP on Pdx1 promoter, pancreas-specific Sirt1 KO mice","pmids":["24163589"],"confidence":"Medium","gaps":["Reconciliation with SIRT1-driven FOXA2 degradation elsewhere not addressed","Direct vs. indirect Pdx1 effect not fully separated"]},{"year":2017,"claim":"Provided the structural basis of FOXA2 DNA recognition, localizing specificity to helix H3 and wing 1 and showing wing 2 contributes to affinity.","evidence":"2.8 Å co-crystal of FOXA2 DBD with consensus DNA and ITC for wing 2 deletion","pmids":["28644006"],"confidence":"High","gaps":["Structure of full-length factor or nucleosome-bound complex not solved","Basis of pioneer activity not captured by naked-DNA structure"]},{"year":2017,"claim":"Linked FOXA2 directly to human Mendelian disease through a DNA-binding-domain mutation impairing transactivation and protein stability.","evidence":"Whole-exome sequencing of patients; WT vs. p.S169P reporter and western blot in HEK293T","pmids":["28973288"],"confidence":"Medium","gaps":["Functional validation limited to transient transfection reporters","In vivo recapitulation of patient phenotype not shown"]},{"year":2019,"claim":"Demonstrated FOXA2 is the pioneer factor priming pancreatic enhancers (H3K4me1) and enabling GATA6 recruitment during human pancreatic specification.","evidence":"CRISPR FOXA2 KO in hPSCs with ATAC-seq, H3K4me1/GATA6 ChIP-seq, directed differentiation","pmids":["31291575"],"confidence":"High","gaps":["Direct FOXA2-GATA6 interaction not biochemically tested","Mechanism of H3K4me1 deposition (which methyltransferase) unresolved"]},{"year":2019,"claim":"Refined the pioneer model: epigenetic priming directs FOXA2 site selection and binding alone is insufficient for opening, which requires synergistic co-binding factors.","evidence":"ATAC-seq, ChIP-seq for active marks, ectopic Foxa2 expression in ESCs with genome-wide binding","pmids":["31350899"],"confidence":"High","gaps":["Identity of all required co-binding partners not enumerated","Quantitative threshold for productive opening not defined"]},{"year":2022,"claim":"Connected DNA demethylation to FOXA2 pioneering, showing TET1 physically interacts with FOXA2 and is required for its binding at pancreatic enhancers.","evidence":"TET triple-KO hESCs, WGBS, ATAC-seq, ChIP-seq, TET1-FOXA2 co-IP, beta-cell differentiation","pmids":["35798741"],"confidence":"High","gaps":["Whether FOXA2 recruits TET1 or vice versa not resolved","Direct demethylation at FOXA2 sites vs. global effects not separated"]},{"year":2007,"claim":"Revealed a repressive FOXA2 role in mature beta cells, where its loss enlarges the docked granule pool and enhances first-phase secretion via trafficking genes.","evidence":"Inducible Pdx1-CreERT2 Foxa2 ablation with EM, Ca2+/cAMP measurement, expression profiling","pmids":["17908556"],"confidence":"High","gaps":["Direct trafficking-gene targets not all mapped","Reconciliation with FOXA2's earlier activating role not addressed"]},{"year":2010,"claim":"Showed FOXA1/FOXA2 redundancy and a direct ChREBP target underlying beta-cell glucose homeostasis.","evidence":"Inducible double conditional KO, islet secretion and Ca2+ assays, ChIP at ChREBP promoter","pmids":["20534694"],"confidence":"High","gaps":["Degree of FOXA1/2 functional non-equivalence not quantified","Downstream metabolic consequences of ChREBP loss not fully traced"]},{"year":2014,"claim":"Identified FOXA1/2 control of glucagon-gene expression and an alpha-cell-specific FOXA2 target set, extending its role across both islet endocrine lineages.","evidence":"siRNA knockdown in alpha cells, ChIP at multiple promoters, glucagon secretion assays","pmids":["25057789"],"confidence":"Medium","gaps":["Mechanism of FOXA2-specific (vs FOXA1) target selectivity unknown","In vivo alpha-cell phenotype not tested"]},{"year":2014,"claim":"Placed FOXA2 within a TXNIP/miR-124a regulatory cascade controlling IAPP transcription in beta cells.","evidence":"ChIP at IAPP promoter, luciferase assays, miR-124a manipulation, beta-cell Txnip KO mice","pmids":["24627476"],"confidence":"Medium","gaps":["Direct FOXA2 regulation by miR-124a vs. indirect not fully separated","Relevance to amyloid pathology not established"]},{"year":2014,"claim":"Defined a neuronal co-activator mechanism: FOXA2 converts the Nurr1-CoREST-HDAC1 repressor into an activator complex, opening dopaminergic gene chromatin.","evidence":"Nurr1/CoREST/Foxa2 co-IP, ChIP for CoREST/Hdac1/H3Ac, reporters, neural precursor differentiation","pmids":["24496614"],"confidence":"High","gaps":["Structural basis of complex switching not resolved","Generality beyond dopaminergic promoters not tested"]},{"year":2015,"claim":"Identified combinatorial maturation circuitry in beta cells, with Insm1, Neurod1, and FOXA2 physically interacting and co-occupying maturity genes.","evidence":"Co-IP, ChIP-seq for all three factors, Insm1 conditional KO, expression profiling","pmids":["25828096"],"confidence":"High","gaps":["Order of complex assembly on chromatin not resolved","Pairwise vs. ternary binding requirements not dissected"]},{"year":2015,"claim":"Placed FOXA2 in an anterior-mesendoderm developmental complex with Lhx1, Otx2, and the chromatin-looper Ldb1.","evidence":"Proteomic co-IP and ChIP-seq for Lhx1/Otx2/Foxa2, conditional Lhx1 inactivation","pmids":["26494787"],"confidence":"Medium","gaps":["Direct binary FOXA2 contacts within the complex not mapped","Functional requirement of FOXA2 within Ldb1 looping not isolated"]},{"year":2018,"claim":"Added a non-genomic arm of hepatic gluconeogenic control, with glucagon-activated FOXA2 physically inhibiting FXR-mediated SHP induction.","evidence":"Pull-down, ChIP-seq, Foxa2 knockdown in primary hepatocytes, transactivation assays, FXR mutagenesis","pmids":["29981427"],"confidence":"Medium","gaps":["Interaction surface on FOXA2 not mapped","In vivo contribution to fasting glycemia not quantified"]},{"year":2022,"claim":"Established FOXA2 as a tumor suppressor that synergizes epistatically with PI3K/PTEN, acting through enhancer modification in endometrial epithelium.","evidence":"Conditional Foxa2/Pten single and double KO mice, RNA-seq, ChIP-seq, organoids, cell assays","pmids":["35703180"],"confidence":"High","gaps":["Mechanistic link between FOXA2 loss and PI3K hyperactivation not fully defined","Key suppressed enhancer targets not pinpointed"]},{"year":2019,"claim":"Showed FOXA2 cistrome and regulated programs are grade-specific in pancreatic cancer, set by differential co-binding partners despite constant expression.","evidence":"ChIP-seq and ATAC-seq across PDAC lines with knockdown validation","pmids":["31531882"],"confidence":"High","gaps":["Identity of grade-specific partner factors not fully resolved","Drivers of differential FOXA2 recruitment unknown"]},{"year":2020,"claim":"Identified upstream epigenetic activation of FOXA2 by PHF8 in neuroendocrine prostate cancer.","evidence":"PHF8 KO in TRAMP mice, ChIP for repressive marks at FOXA2 promoter, xenografts","pmids":["33009820"],"confidence":"Medium","gaps":["Direct PHF8 demethylation at FOXA2 promoter vs. indirect not separated","Generality across NEPC models not tested"]},{"year":2022,"claim":"Established FOXA2 as a driver of prostate adeno-to-neuroendocrine lineage transition induced by androgen deprivation, acting through the KIT pathway.","evidence":"Single-cell multiomics in GEMMs, FOXA2 knockdown rescue, KIT inhibition, human NEPC analysis","pmids":["36332622"],"confidence":"High","gaps":["Direct vs. indirect KIT regulation not fully separated","Initiating trigger of FOXA2 induction not defined"]},{"year":2024,"claim":"Defined the mechanism of FOXA2 lineage reprogramming in AR-independent prostate cancer through LSD1-dependent enhancer binding and JUN/AP-1 collaboration.","evidence":"FOXA2/JUN ChIP-seq, ATAC-seq, LSD1 inhibition, FOXA2 overexpression in PCa lines","pmids":["38851846"],"confidence":"High","gaps":["Direct FOXA2-LSD1 and FOXA2-JUN physical contacts not biochemically mapped","Reversibility of reprogrammed states not tested"]},{"year":2023,"claim":"Added a degradation pathway: the E3 ligase TRIM36 drives K48-polyubiquitination and proteasomal turnover of FOXA2, linking FOXA2 levels to ferroptosis control via NRF2/GPX4.","evidence":"TRIM36-FOXA2 co-IP, K48 ubiquitination assays, FOXA2 depletion, NRF2/GPX4 analysis in colorectal cells","pmids":["37875418"],"confidence":"Medium","gaps":["Ubiquitination acceptor lysines on FOXA2 not mapped","Direct vs. indirect NRF2/GPX4 regulation not separated"]},{"year":2021,"claim":"Identified a cardioprotective transcriptional-repressor role, with FOXA2 directly silencing RIPK3 to limit necroptosis via the CNEACR/HDAC7/Foxa2 axis.","evidence":"ChIP at RIPK3 promoter, FOXA2 OE/KD in cardiomyocytes, H/R injury model, HDAC7 fractionation","pmids":["34588633"],"confidence":"Medium","gaps":["Direct repression mechanism (co-repressor recruitment) not defined","Generality to in vivo ischemia not fully established"]},{"year":2010,"claim":"Linked FOXA2 to immune homeostasis, showing respiratory-epithelial FOXA2 suppresses Th2 inflammation via a defined cytokine/chemokine program.","evidence":"Respiratory-epithelium Foxa2 conditional KO with cytokine profiling, flow cytometry, anti-IL-4Rα rescue","pmids":["20483781"],"confidence":"Medium","gaps":["Direct FOXA2 cytokine-gene targets not all defined","Whether repression is direct or indirect unresolved"]},{"year":2013,"claim":"Showed FOXA2 stability is regulated by Hippo kinases Mst1/2 in lung, required for pneumocyte differentiation and surfactant expression, independent of YAP.","evidence":"Mst1/2 conditional KO mice, Foxa2 phosphorylation/co-IP assays, surfactant gene analysis","pmids":["23620511"],"confidence":"Medium","gaps":["Phosphosite(s) mediating Mst1/2 stabilization not mapped","Mechanism of stabilization (degradation block) unresolved"]},{"year":null,"claim":"It remains unresolved how the diverse PTM inputs (Thr156 phosphorylation, Lys259 acetylation, Lys6 sumoylation, Ser107/111 phosphorylation, K48 ubiquitination) are integrated into a single quantitative control of FOXA2 activity, and what structural basis allows the same factor to act as activator, repressor, tumor suppressor, and lineage-reprogramming oncogenic driver across tissues.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structure of FOXA2 engaging a nucleosome to explain pioneer activity","No unified model reconciling context-dependent activating vs. repressive and tumor-suppressive vs. oncogenic roles","Direct physical contacts to most named co-factors not biochemically mapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[11,7,35]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[1,13,20,29]},{"term_id":"GO:0140097","term_label":"catalytic activity, acting on DNA","supporting_discovery_ids":[12,13]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,6]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[13,12]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[1,13,20]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[13,18,22,40]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[12,13,14,15]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,1,2,7]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[31,32,37,23]}],"complexes":["Insm1-Neurod1-FOXA2 beta-cell maturity complex","Lhx1-Otx2-FOXA2-Ldb1 anterior mesendoderm complex","Nurr1-FOXA2 dopaminergic activator complex"],"partners":["GATA6","HNF4A","FXR","SIRT1","NURR1","INSM1","JUN","TET1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9Y261","full_name":"Hepatocyte nuclear factor 3-beta","aliases":["Forkhead box protein A2","Transcription factor 3B","TCF-3B"],"length_aa":457,"mass_kda":48.3,"function":"Transcription factor that is involved in embryonic development, establishment of tissue-specific gene expression and regulation of gene expression in differentiated tissues. Is thought to act as a 'pioneer' factor opening the compacted chromatin for other proteins through interactions with nucleosomal core histones and thereby replacing linker histones at target enhancer and/or promoter sites. Binds DNA with the consensus sequence 5'-[AC]A[AT]T[AG]TT[GT][AG][CT]T[CT]-3' (By similarity). In embryonic development is required for notochord formation. Involved in the development of multiple endoderm-derived organ systems such as the liver, pancreas and lungs; FOXA1 and FOXA2 seem to have at least in part redundant roles. Originally described as a transcription activator for a number of liver genes such as AFP, albumin, tyrosine aminotransferase, PEPCK, etc. Interacts with the cis-acting regulatory regions of these genes. Involved in glucose homeostasis; regulates the expression of genes important for glucose sensing in pancreatic beta-cells and glucose homeostasis. Involved in regulation of fat metabolism. Binds to fibrinogen beta promoter and is involved in IL6-induced fibrinogen beta transcriptional activation","subcellular_location":"Nucleus; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q9Y261/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FOXA2","classification":"Not Classified","n_dependent_lines":58,"n_total_lines":1208,"dependency_fraction":0.048013245033112585},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FOXA2","total_profiled":1310},"omim":[{"mim_id":"620874","title":"ADHESION G PROTEIN-COUPLED RECEPTOR F5; ADGRF5","url":"https://www.omim.org/entry/620874"},{"mim_id":"618656","title":"PROLINE- AND GLUTAMATE-RICH PROTEIN WITH COILED-COIL DOMAIN 1; PERCC1","url":"https://www.omim.org/entry/618656"},{"mim_id":"618518","title":"LONG INTERGENIC NONCODING RNA 261; LINC00261","url":"https://www.omim.org/entry/618518"},{"mim_id":"616119","title":"CILIA- AND FLAGELLA-ASSOCIATED PROTEIN 126; CFAP126","url":"https://www.omim.org/entry/616119"},{"mim_id":"613555","title":"TET METHYLCYTOSINE DIOXYGENASE 3; TET3","url":"https://www.omim.org/entry/613555"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Cell Junctions","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"liver","ntpm":34.8},{"tissue":"pancreas","ntpm":25.2},{"tissue":"stomach 1","ntpm":29.3}],"url":"https://www.proteinatlas.org/search/FOXA2"},"hgnc":{"alias_symbol":[],"prev_symbol":["HNF3B"]},"alphafold":{"accession":"Q9Y261","domains":[{"cath_id":"1.10.10.10","chopping":"165-268","consensus_level":"high","plddt":85.8162,"start":165,"end":268}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9Y261","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9Y261-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9Y261-F1-predicted_aligned_error_v6.png","plddt_mean":56.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FOXA2","jax_strain_url":"https://www.jax.org/strain/search?query=FOXA2"},"sequence":{"accession":"Q9Y261","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9Y261.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9Y261/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9Y261"}},"corpus_meta":[{"pmid":"15616563","id":"PMC_15616563","title":"Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes.","date":"2004","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/15616563","citation_count":338,"is_preprint":false},{"pmid":"22265403","id":"PMC_22265403","title":"Foxa1 and Foxa2 are essential for sexual dimorphism in liver cancer.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22265403","citation_count":325,"is_preprint":false},{"pmid":"17462994","id":"PMC_17462994","title":"MicroRNA-124a regulates Foxa2 expression and intracellular signaling in pancreatic beta-cell lines.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17462994","citation_count":275,"is_preprint":false},{"pmid":"17596284","id":"PMC_17596284","title":"Foxa1 and Foxa2 regulate multiple phases of midbrain dopaminergic neuron development in a dosage-dependent manner.","date":"2007","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/17596284","citation_count":236,"is_preprint":false},{"pmid":"14757645","id":"PMC_14757645","title":"Foxa2 regulates alveolarization and goblet cell hyperplasia.","date":"2004","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/14757645","citation_count":227,"is_preprint":false},{"pmid":"15668254","id":"PMC_15668254","title":"Compensatory roles of Foxa1 and Foxa2 during lung morphogenesis.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15668254","citation_count":224,"is_preprint":false},{"pmid":"15567715","id":"PMC_15567715","title":"Immunohistochemical localization of Foxa1 and Foxa2 in mouse embryos and adult tissues.","date":"2004","source":"Gene expression patterns : GEP","url":"https://pubmed.ncbi.nlm.nih.gov/15567715","citation_count":186,"is_preprint":false},{"pmid":"20484741","id":"PMC_20484741","title":"Foxa2 is essential for mouse endometrial gland development and fertility.","date":"2010","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/20484741","citation_count":186,"is_preprint":false},{"pmid":"23260146","id":"PMC_23260146","title":"Foxa2 and H2A.Z mediate nucleosome depletion during embryonic stem cell differentiation.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/23260146","citation_count":169,"is_preprint":false},{"pmid":"19234065","id":"PMC_19234065","title":"Foxa2 regulates polarity and epithelialization in the endoderm germ layer of the mouse embryo.","date":"2009","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/19234065","citation_count":167,"is_preprint":false},{"pmid":"16098831","id":"PMC_16098831","title":"Foxa2 integrates the transcriptional response of the hepatocyte to fasting.","date":"2005","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/16098831","citation_count":152,"is_preprint":false},{"pmid":"28049832","id":"PMC_28049832","title":"Forkhead box a2 (FOXA2) is essential for uterine function and fertility.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/28049832","citation_count":147,"is_preprint":false},{"pmid":"15314688","id":"PMC_15314688","title":"Foxa2 regulates multiple pathways of insulin secretion.","date":"2004","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/15314688","citation_count":145,"is_preprint":false},{"pmid":"19737569","id":"PMC_19737569","title":"Foxa1 and Foxa2 control the differentiation of goblet and enteroendocrine L- and D-cells in mice.","date":"2009","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/19737569","citation_count":131,"is_preprint":false},{"pmid":"36332622","id":"PMC_36332622","title":"FOXA2 drives lineage plasticity and KIT pathway activation in neuroendocrine prostate cancer.","date":"2022","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/36332622","citation_count":129,"is_preprint":false},{"pmid":"31291575","id":"PMC_31291575","title":"FOXA2 Is Required for Enhancer Priming during Pancreatic Differentiation.","date":"2019","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/31291575","citation_count":121,"is_preprint":false},{"pmid":"19607821","id":"PMC_19607821","title":"Foxa1 and Foxa2 function both upstream of and cooperatively with Lmx1a and Lmx1b in a feedforward loop promoting mesodiencephalic dopaminergic neuron development.","date":"2009","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/19607821","citation_count":116,"is_preprint":false},{"pmid":"19436110","id":"PMC_19436110","title":"Foxa1 and Foxa2 regulate bile duct development in mice.","date":"2009","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/19436110","citation_count":114,"is_preprint":false},{"pmid":"15452354","id":"PMC_15452354","title":"Foxa2 is required for transition to air breathing at birth.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15452354","citation_count":108,"is_preprint":false},{"pmid":"20534694","id":"PMC_20534694","title":"Foxa1 and Foxa2 maintain the metabolic and secretory features of the mature beta-cell.","date":"2010","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/20534694","citation_count":98,"is_preprint":false},{"pmid":"25263553","id":"PMC_25263553","title":"Hippo signaling influences HNF4A and FOXA2 enhancer switching during hepatocyte differentiation.","date":"2014","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/25263553","citation_count":94,"is_preprint":false},{"pmid":"23416070","id":"PMC_23416070","title":"Glucagon-induced acetylation of Foxa2 regulates hepatic lipid metabolism.","date":"2013","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/23416070","citation_count":93,"is_preprint":false},{"pmid":"28621319","id":"PMC_28621319","title":"FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate.","date":"2017","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/28621319","citation_count":91,"is_preprint":false},{"pmid":"26341558","id":"PMC_26341558","title":"Foxa2 and Cdx2 cooperate with Nkx2-1 to inhibit lung adenocarcinoma metastasis.","date":"2015","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/26341558","citation_count":85,"is_preprint":false},{"pmid":"26494787","id":"PMC_26494787","title":"Lhx1 functions together with Otx2, Foxa2, and Ldb1 to govern anterior mesendoderm, node, and midline development.","date":"2015","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/26494787","citation_count":84,"is_preprint":false},{"pmid":"29748371","id":"PMC_29748371","title":"miR-590-3p Promotes Ovarian Cancer Growth and Metastasis via a Novel FOXA2-Versican Pathway.","date":"2018","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/29748371","citation_count":80,"is_preprint":false},{"pmid":"16467259","id":"PMC_16467259","title":"Foxa1 and Foxa2 interact with the androgen receptor to regulate prostate and epididymal genes differentially.","date":"2005","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/16467259","citation_count":80,"is_preprint":false},{"pmid":"20049900","id":"PMC_20049900","title":"Foxa2 and Nurr1 synergistically yield A9 nigral dopamine neurons exhibiting improved differentiation, function, and cell survival.","date":"2010","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/20049900","citation_count":80,"is_preprint":false},{"pmid":"22196886","id":"PMC_22196886","title":"IKKα activation of NOTCH links tumorigenesis via FOXA2 suppression.","date":"2011","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/22196886","citation_count":80,"is_preprint":false},{"pmid":"25828096","id":"PMC_25828096","title":"Insm1 cooperates with Neurod1 and Foxa2 to maintain mature pancreatic β-cell function.","date":"2015","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/25828096","citation_count":79,"is_preprint":false},{"pmid":"25759364","id":"PMC_25759364","title":"Combined Nurr1 and Foxa2 roles in the therapy of Parkinson's disease.","date":"2015","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25759364","citation_count":79,"is_preprint":false},{"pmid":"35154496","id":"PMC_35154496","title":"Ginger nanoparticles mediated induction of Foxa2 prevents high-fat diet-induced insulin resistance.","date":"2022","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/35154496","citation_count":78,"is_preprint":false},{"pmid":"20483781","id":"PMC_20483781","title":"Foxa2 programs Th2 cell-mediated innate immunity in the developing lung.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/20483781","citation_count":77,"is_preprint":false},{"pmid":"25083987","id":"PMC_25083987","title":"Hedgehog signaling regulates FOXA2 in esophageal embryogenesis and Barrett's metaplasia.","date":"2014","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/25083987","citation_count":77,"is_preprint":false},{"pmid":"17908556","id":"PMC_17908556","title":"Foxa2 controls vesicle docking and insulin secretion in mature Beta cells.","date":"2007","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/17908556","citation_count":75,"is_preprint":false},{"pmid":"28195173","id":"PMC_28195173","title":"Foxa2 identifies a cardiac progenitor population with ventricular differentiation potential.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/28195173","citation_count":73,"is_preprint":false},{"pmid":"19628779","id":"PMC_19628779","title":"Distinct roles of FOXA2 and FOXA3 in allergic airway disease and asthma.","date":"2009","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19628779","citation_count":72,"is_preprint":false},{"pmid":"25249938","id":"PMC_25249938","title":"Transcription factors Foxa1 and Foxa2 are required for adult dopamine neurons maintenance.","date":"2014","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/25249938","citation_count":71,"is_preprint":false},{"pmid":"34588633","id":"PMC_34588633","title":"The circRNA CNEACR regulates necroptosis of cardiomyocytes through Foxa2 suppression.","date":"2021","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/34588633","citation_count":70,"is_preprint":false},{"pmid":"28580283","id":"PMC_28580283","title":"Foxa2 and Pdx1 cooperatively regulate postnatal maturation of pancreatic β-cells.","date":"2017","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/28580283","citation_count":69,"is_preprint":false},{"pmid":"31350899","id":"PMC_31350899","title":"Pre-marked chromatin and transcription factor co-binding shape the pioneering activity of Foxa2.","date":"2019","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/31350899","citation_count":68,"is_preprint":false},{"pmid":"30475207","id":"PMC_30475207","title":"FoxA1 and FoxA2 drive gastric differentiation and suppress squamous identity in NKX2-1-negative lung cancer.","date":"2018","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/30475207","citation_count":66,"is_preprint":false},{"pmid":"15677724","id":"PMC_15677724","title":"Monorail/Foxa2 regulates floorplate differentiation and specification of oligodendrocytes, serotonergic raphé neurones and cranial motoneurones.","date":"2005","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/15677724","citation_count":66,"is_preprint":false},{"pmid":"23620511","id":"PMC_23620511","title":"Hippo-Foxa2 signaling pathway plays a role in peripheral lung maturation and surfactant homeostasis.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/23620511","citation_count":65,"is_preprint":false},{"pmid":"37875418","id":"PMC_37875418","title":"FOXA2 Suppression by TRIM36 Exerts Anti-Tumor Role in Colorectal Cancer Via Inducing NRF2/GPX4-Regulated Ferroptosis.","date":"2023","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/37875418","citation_count":62,"is_preprint":false},{"pmid":"28973288","id":"PMC_28973288","title":"Novel FOXA2 mutation causes Hyperinsulinism, Hypopituitarism with Craniofacial and Endoderm-derived organ abnormalities.","date":"2017","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28973288","citation_count":60,"is_preprint":false},{"pmid":"19822575","id":"PMC_19822575","title":"Molecular interactions between HNF4a, FOXA2 and GABP identified at regulatory DNA elements through ChIP-sequencing.","date":"2009","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/19822575","citation_count":58,"is_preprint":false},{"pmid":"24627476","id":"PMC_24627476","title":"Thioredoxin-interacting protein promotes islet amyloid polypeptide expression through miR-124a and FoxA2.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24627476","citation_count":57,"is_preprint":false},{"pmid":"38605023","id":"PMC_38605023","title":"FOXA1 and FOXA2: the regulatory mechanisms and therapeutic implications in cancer.","date":"2024","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/38605023","citation_count":55,"is_preprint":false},{"pmid":"21093585","id":"PMC_21093585","title":"Foxa1 and Foxa2 positively and negatively regulate Shh signalling to specify ventral midbrain progenitor identity.","date":"2010","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/21093585","citation_count":52,"is_preprint":false},{"pmid":"33009820","id":"PMC_33009820","title":"Histone demethylase PHF8 drives neuroendocrine prostate cancer progression by epigenetically upregulating FOXA2.","date":"2020","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/33009820","citation_count":52,"is_preprint":false},{"pmid":"29981427","id":"PMC_29981427","title":"The nuclear bile acid receptor FXR is a PKA- and FOXA2-sensitive activator of fasting hepatic gluconeogenesis.","date":"2018","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/29981427","citation_count":51,"is_preprint":false},{"pmid":"25057789","id":"PMC_25057789","title":"Foxa1 and Foxa2 regulate α-cell differentiation, glucagon biosynthesis, and secretion.","date":"2014","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/25057789","citation_count":48,"is_preprint":false},{"pmid":"27151939","id":"PMC_27151939","title":"Transcriptomic and CRISPR/Cas9 technologies reveal FOXA2 as a tumor suppressor gene in pancreatic cancer.","date":"2016","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/27151939","citation_count":48,"is_preprint":false},{"pmid":"35523895","id":"PMC_35523895","title":"A FoxA2+ long-term stem cell population is necessary for growth plate cartilage regeneration after injury.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35523895","citation_count":48,"is_preprint":false},{"pmid":"33288882","id":"PMC_33288882","title":"Selective inhibition of stemness through EGFR/FOXA2/SOX9 axis reduces pancreatic cancer metastasis.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/33288882","citation_count":48,"is_preprint":false},{"pmid":"22945641","id":"PMC_22945641","title":"β-Catenin signaling regulates Foxa2 expression during endometrial hyperplasia formation.","date":"2012","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/22945641","citation_count":45,"is_preprint":false},{"pmid":"35835117","id":"PMC_35835117","title":"FoxA1 and FoxA2 control growth and cellular identity in NKX2-1-positive lung adenocarcinoma.","date":"2022","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/35835117","citation_count":43,"is_preprint":false},{"pmid":"24163589","id":"PMC_24163589","title":"SIRT1 deacetylates FOXA2 and is critical for Pdx1 transcription and β-cell formation.","date":"2013","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/24163589","citation_count":42,"is_preprint":false},{"pmid":"30576223","id":"PMC_30576223","title":"The Club Cell Marker SCGB1A1 Downstream of FOXA2 is Reduced in Asthma.","date":"2019","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/30576223","citation_count":42,"is_preprint":false},{"pmid":"24496614","id":"PMC_24496614","title":"Foxa2 acts as a co-activator potentiating expression of the Nurr1-induced DA phenotype via epigenetic regulation.","date":"2014","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/24496614","citation_count":42,"is_preprint":false},{"pmid":"31531882","id":"PMC_31531882","title":"FOXA2 controls the cis-regulatory networks of pancreatic cancer cells in a differentiation grade-specific manner.","date":"2019","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/31531882","citation_count":41,"is_preprint":false},{"pmid":"28644006","id":"PMC_28644006","title":"Structure of the Forkhead Domain of FOXA2 Bound to a Complete DNA Consensus Site.","date":"2017","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28644006","citation_count":39,"is_preprint":false},{"pmid":"32176463","id":"PMC_32176463","title":"LncRNA FTX activates FOXA2 expression to inhibit non-small-cell lung cancer proliferation and metastasis.","date":"2020","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32176463","citation_count":38,"is_preprint":false},{"pmid":"28450970","id":"PMC_28450970","title":"Aberrant DNA methylation and expression of SPDEF and FOXA2 in airway epithelium of patients with COPD.","date":"2017","source":"Clinical epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/28450970","citation_count":38,"is_preprint":false},{"pmid":"29896233","id":"PMC_29896233","title":"FOXA2 promotes the proliferation, migration and invasion, and epithelial mesenchymal transition in colon cancer.","date":"2018","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29896233","citation_count":38,"is_preprint":false},{"pmid":"29138513","id":"PMC_29138513","title":"FOXA2 alleviates CCl4-induced liver fibrosis by protecting hepatocytes in mice.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29138513","citation_count":38,"is_preprint":false},{"pmid":"33144666","id":"PMC_33144666","title":"Embryonic liver developmental trajectory revealed by single-cell RNA sequencing in the Foxa2eGFP mouse.","date":"2020","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/33144666","citation_count":37,"is_preprint":false},{"pmid":"27322206","id":"PMC_27322206","title":"MicroRNA-1291 targets the FOXA2-AGR2 pathway to suppress pancreatic cancer cell proliferation and tumorigenesis.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27322206","citation_count":37,"is_preprint":false},{"pmid":"26684323","id":"PMC_26684323","title":"Brachyury, Foxa2 and the cis-Regulatory Origins of the Notochord.","date":"2015","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26684323","citation_count":36,"is_preprint":false},{"pmid":"33448076","id":"PMC_33448076","title":"The pioneer and differentiation factor FOXA2 is a key driver of yolk-sac tumour formation and a new biomarker for paediatric and adult yolk-sac tumours.","date":"2021","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33448076","citation_count":36,"is_preprint":false},{"pmid":"32269574","id":"PMC_32269574","title":"Inactivation of FOXA2 by Respiratory Bacterial Pathogens and Dysregulation of Pulmonary Mucus Homeostasis.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32269574","citation_count":34,"is_preprint":false},{"pmid":"23471965","id":"PMC_23471965","title":"Neurogenin3 cooperates with Foxa2 to autoactivate its own expression.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23471965","citation_count":34,"is_preprint":false},{"pmid":"38851846","id":"PMC_38851846","title":"FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38851846","citation_count":32,"is_preprint":false},{"pmid":"29329447","id":"PMC_29329447","title":"Congenital Hyperinsulinism and Hypopituitarism Attributable to a Mutation in FOXA2.","date":"2018","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/29329447","citation_count":31,"is_preprint":false},{"pmid":"21037926","id":"PMC_21037926","title":"The Siah2-HIF-FoxA2 axis in prostate cancer – new markers and therapeutic opportunities.","date":"2010","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/21037926","citation_count":30,"is_preprint":false},{"pmid":"28367241","id":"PMC_28367241","title":"MicroRNA-200a inhibits cell growth and metastasis by targeting Foxa2 in hepatocellular carcinoma.","date":"2017","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28367241","citation_count":29,"is_preprint":false},{"pmid":"32495363","id":"PMC_32495363","title":"FoxA2 inhibits the proliferation of hepatic progenitor cells by reducing PI3K/Akt/HK2-mediated glycolysis.","date":"2020","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/32495363","citation_count":28,"is_preprint":false},{"pmid":"32034274","id":"PMC_32034274","title":"Exendin-4 restores airway mucus homeostasis through the GLP1R-PKA-PPARγ-FOXA2-phosphatase signaling.","date":"2020","source":"Mucosal immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32034274","citation_count":28,"is_preprint":false},{"pmid":"30923168","id":"PMC_30923168","title":"The long noncoding RNA Falcor regulates Foxa2 expression to maintain lung epithelial homeostasis and promote regeneration.","date":"2019","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/30923168","citation_count":28,"is_preprint":false},{"pmid":"21385937","id":"PMC_21385937","title":"Dynamic regulation of PDX-1 and FoxO1 expression by FoxA2 in dexamethasone-induced pancreatic β-cells dysfunction.","date":"2011","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21385937","citation_count":28,"is_preprint":false},{"pmid":"36289750","id":"PMC_36289750","title":"CD44 Promotes Breast Cancer Metastasis through AKT-Mediated Downregulation of Nuclear FOXA2.","date":"2022","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/36289750","citation_count":28,"is_preprint":false},{"pmid":"28940304","id":"PMC_28940304","title":"The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.","date":"2017","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28940304","citation_count":28,"is_preprint":false},{"pmid":"19417011","id":"PMC_19417011","title":"Foxa2-dependent hepatic gene regulatory networks depend on physiological state.","date":"2009","source":"Physiological genomics","url":"https://pubmed.ncbi.nlm.nih.gov/19417011","citation_count":27,"is_preprint":false},{"pmid":"22607194","id":"PMC_22607194","title":"GATA6 and FOXA2 regulate Wnt6 expression during extraembryonic endoderm formation.","date":"2012","source":"Stem cells and development","url":"https://pubmed.ncbi.nlm.nih.gov/22607194","citation_count":26,"is_preprint":false},{"pmid":"37471707","id":"PMC_37471707","title":"Gambogenic acid inhibits proliferation and ferroptosis by targeting the miR-1291/FOXA2 and AMPKα/SLC7A11/GPX4 axis in colorectal cancer.","date":"2023","source":"Cell biology international","url":"https://pubmed.ncbi.nlm.nih.gov/37471707","citation_count":25,"is_preprint":false},{"pmid":"33927349","id":"PMC_33927349","title":"MRE11 promotes oral cancer progression through RUNX2/CXCR4/AKT/FOXA2 signaling in a nuclease-independent manner.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/33927349","citation_count":25,"is_preprint":false},{"pmid":"24970044","id":"PMC_24970044","title":"Developmental lung expression and transcriptional regulation of claudin-6 by TTF-1, Gata-6, and FoxA2.","date":"2014","source":"Respiratory research","url":"https://pubmed.ncbi.nlm.nih.gov/24970044","citation_count":25,"is_preprint":false},{"pmid":"28098868","id":"PMC_28098868","title":"MicroRNA-187 promotes growth and metastasis of gastric cancer by inhibiting FOXA2.","date":"2017","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/28098868","citation_count":25,"is_preprint":false},{"pmid":"35703180","id":"PMC_35703180","title":"FOXA2 suppresses endometrial carcinogenesis and epithelial-mesenchymal transition by regulating enhancer activity.","date":"2022","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/35703180","citation_count":24,"is_preprint":false},{"pmid":"24875183","id":"PMC_24875183","title":"SIRT1 mediates FOXA2 breakdown by deacetylation in a nutrient-dependent manner.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24875183","citation_count":24,"is_preprint":false},{"pmid":"25749777","id":"PMC_25749777","title":"Expression and Regulation of Transcription Factor FoxA2 in Chronic Rhinosinusitis With and Without Nasal Polyps.","date":"2015","source":"Allergy, asthma & immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/25749777","citation_count":23,"is_preprint":false},{"pmid":"23275033","id":"PMC_23275033","title":"Foxa2 may modulate hepatic apoptosis through the cIAP1 pathway.","date":"2012","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/23275033","citation_count":23,"is_preprint":false},{"pmid":"37315133","id":"PMC_37315133","title":"Yap controls notochord formation and neural tube patterning by integrating mechanotransduction with FoxA2 and Shh expression.","date":"2023","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/37315133","citation_count":22,"is_preprint":false},{"pmid":"35798741","id":"PMC_35798741","title":"TET1 dioxygenase is required for FOXA2-associated chromatin remodeling in pancreatic beta-cell differentiation.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35798741","citation_count":22,"is_preprint":false},{"pmid":"37317674","id":"PMC_37317674","title":"FoxA2 is a reliable marker for the diagnosis of yolk sac tumour postpubertal-type.","date":"2023","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/37317674","citation_count":22,"is_preprint":false},{"pmid":"23118920","id":"PMC_23118920","title":"Forkhead box protein A2 (FOXA2) protein stability and activity are regulated by sumoylation.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23118920","citation_count":21,"is_preprint":false},{"pmid":"26890743","id":"PMC_26890743","title":"Meta-Analysis of Transcriptome Data Related to Hippocampus Biopsies and iPSC-Derived Neuronal Cells from Alzheimer's Disease Patients Reveals an Association with FOXA1 and FOXA2 Gene Regulatory Networks.","date":"2016","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/26890743","citation_count":21,"is_preprint":false},{"pmid":"31701999","id":"PMC_31701999","title":"MiR-942 regulates the function of breast cancer cell by targeting FOXA2.","date":"2019","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/31701999","citation_count":21,"is_preprint":false},{"pmid":"33473118","id":"PMC_33473118","title":"Aberrant development of pancreatic beta cells derived from human iPSCs with FOXA2 deficiency.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/33473118","citation_count":21,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49852,"output_tokens":11123,"usd":0.1582,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":22134,"output_tokens":9952,"usd":0.179735,"stage2_stop_reason":"end_turn"},"total_usd":0.337935,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2004,\n      \"finding\": \"Insulin signaling causes nuclear exclusion of Foxa2 (phosphorylation-dependent cytoplasmic localization), inactivating its transcriptional program; a constitutively nuclear Foxa2T156A mutant (cannot be phosphorylated by insulin/PI3K/Akt) activates lipid oxidation, ketogenesis, and glycolysis gene programs in the liver, demonstrating that insulin inhibits Foxa2 by nuclear exclusion.\",\n      \"method\": \"Adenoviral expression of Foxa2T156A in insulin-resistant mice; nuclear/cytoplasmic fractionation; gene expression analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — phosphorylation-site mutagenesis combined with in vivo adenoviral rescue in multiple mouse models, replicated functionally\",\n      \"pmids\": [\"15616563\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Foxa2 is required in hepatocytes for activation of gluconeogenic gene programs during fasting; it acts as a chromatin-level co-activator enabling recruitment of CREB and glucocorticoid receptor (GR) to their target sites, integrating cAMP and glucocorticoid hormone signals.\",\n      \"method\": \"Cell-type-specific Foxa2 gene ablation; chromatin immunoprecipitation (ChIP) for CREB and GR occupancy at gluconeogenic promoters\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with defined molecular phenotype plus ChIP demonstrating impaired co-factor recruitment, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"16098831\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Glucagon induces acetylation of Foxa2 at the conserved residue Lys259; the co-activator p300 acetylates Foxa2 and SirT1 deacetylates it; acetylation-mimicking mutation K259Q increases Foxa2 transcriptional activity on fatty acid oxidation and ketogenesis genes, while K259R reduces it, establishing glucagon-induced acetylation as a positive regulatory PTM.\",\n      \"method\": \"Site-directed mutagenesis (K259Q/K259R); HDAC inhibitor treatment; co-immunoprecipitation of p300 and SirT1 with Foxa2; adenoviral expression in mice; gene expression analysis\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro mutagenesis, co-IP of writer/eraser, in vivo adenoviral rescue; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"23416070\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SIRT1 physically interacts with FOXA2, deacetylates it in a nutrient-dependent manner, and targets it for proteasomal degradation; during starvation, the SIRT1-FOXA2 interaction is reduced, FOXA2 acetylation increases, and FOXA2 is stabilized, enabling its transcriptional program (G6pase, CPT1a) in liver.\",\n      \"method\": \"LC-MS/MS identification of five acetylated FOXA2 residues; co-IP of SIRT1 with FOXA2; siRNA knockdown of UBC9; promoter-reporter assays; murine starvation model\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — mass spectrometry identification of acetylation sites, co-IP, functional mutagenesis, and in vivo starvation experiments; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"24875183\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"SIRT1 forms a protein complex with FOXA2 on the Pdx1 gene promoter; SIRT1 deacetylates FOXA2 and positively regulates Pdx1 transcription in pancreatic beta cells; pancreas-specific SIRT1 disruption diminishes PDX1 expression and impairs islet development.\",\n      \"method\": \"Co-immunoprecipitation; ChIP on Pdx1 promoter; pancreas-specific Sirt1 knockout mice\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP and ChIP in same study, single lab\",\n      \"pmids\": [\"24163589\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"IKKα (downstream of TNFα) phosphorylates FOXA2 at Ser107/Ser111, suppressing FOXA2 transactivation activity, reducing NUMB expression, and consequently activating NOTCH1 signaling to promote hepatocellular carcinoma cell proliferation; this defines a TNFα/IKKα/FOXA2/NUMB/NOTCH1 pathway.\",\n      \"method\": \"Co-immunoprecipitation of IKKα with FOXA2; phospho-specific antibody staining; transactivation reporter assays; knockdown experiments in cell lines and tumor tissue analysis\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct phosphorylation by identified kinase, co-IP, transactivation assay, in vivo tumor correlation; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"22196886\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"FOXA2 is sumoylated at Lys6 by SUMO-1; preventing sumoylation (K6R mutation) destabilizes FOXA2 protein (promotes proteasomal degradation) without affecting nuclear localization; PIAS1 SUMO ligase increases FOXA2 levels and transcriptional activity on Pdx-1 enhancer; UBC9 knockdown reduces FOXA2 protein levels.\",\n      \"method\": \"Site-directed mutagenesis (K6R); SUMO-1 in-frame fusion rescue; siRNA knockdown of UBC9; co-immunoprecipitation with PIAS1; promoter-reporter assays in INS-1E, HepG2, and other cell lines\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — mutagenesis of SUMO acceptor site, identification of E2/E3 enzymes, rescue by direct fusion; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"23118920\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Foxa2 is required in pancreatic beta cells for expression of both Kir6.2 and SUR1 (ATP-sensitive K+ channel subunits) and Hadhsc; Foxa2 directly binds and activates the Hadhsc promoter; loss of Foxa2 causes excessive insulin release to amino acids and complete loss of glucose-stimulated insulin secretion.\",\n      \"method\": \"Conditional beta-cell-specific Foxa2 deletion; isolated islet functional assays; RNA in situ hybridization; chromatin immunoprecipitation; cotransfection reporter assays\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — conditional KO mouse with functional islet assays plus ChIP and cotransfection to confirm direct Hadhsc target; multiple orthogonal methods\",\n      \"pmids\": [\"15314688\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Inducible deletion of Foxa2 in mature beta cells increases the docked insulin granule pool and first-phase glucose-stimulated insulin secretion; Foxa2 regulates expression of multiple genes in vesicular trafficking and membrane targeting, and its loss alters intracellular Ca2+ oscillations and elevates cAMP.\",\n      \"method\": \"Inducible Foxa2 gene ablation (Pdx1-CreERT2); electron microscopy of granule pools; Ca2+ oscillation measurements; cAMP measurement; expression profiling\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — inducible conditional KO with multiple cellular phenotype readouts; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"17908556\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Simultaneous inducible ablation of Foxa1 and Foxa2 in mature beta cells impairs glucose homeostasis and insulin secretion more severely than loss of Foxa2 alone; both factors directly regulate ChREBP (Mlxipl) expression in fetal endocrine pancreas and adult islets.\",\n      \"method\": \"Inducible double conditional KO; isolated islet secretion assays; Ca2+ oscillation measurements; ChIP for Foxa1/Foxa2 at ChREBP promoter; expression profiling\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — inducible double KO with functional assays and ChIP confirmation of direct target; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"20534694\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Insm1, Neurod1, and Foxa2 physically interact and co-occupy regulatory sequences in mature pancreatic beta-cell genomes; combinatorial binding of all three factors explains a significant fraction of gene expression changes needed to maintain beta-cell maturity.\",\n      \"method\": \"Co-immunoprecipitation of Insm1 with Neurod1 and Foxa2; ChIP-seq for all three factors; Insm1 beta-cell-specific ablation; gene expression profiling\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — co-IP plus ChIP-seq plus conditional KO all in the same study; multiple orthogonal methods\",\n      \"pmids\": [\"25828096\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Crystal structure (2.8 Å) of the FOXA2 DNA-binding domain bound to the forkhead consensus site (GTAAACA) shows helix H3 and wing 1 mediate DNA recognition via the canonical winged-helix fold, with more major-groove and fewer minor-groove contacts than FOXA3; wing 2 is required for optimal binding (ITC).\",\n      \"method\": \"X-ray crystallography (2.8 Å co-crystal); isothermal titration calorimetry (ITC) for wing 2 deletion\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure with functional validation by ITC; single study but rigorous structural method\",\n      \"pmids\": [\"28644006\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Foxa2 and the histone variant H2A.Z cooperate to mediate nucleosome depletion at endodermal gene loci during ES cell differentiation into endoderm; nucleosome depletion is dependent on Nap1l1-coupled SWI/SNF and INO80 chromatin remodeling complexes; DNA methylation promotes nucleosome occupation and suppresses gene expression.\",\n      \"method\": \"MNase-seq for nucleosome occupancy; Foxa2 knockdown during ES differentiation; ChIP-seq; pharmacological inhibition of SWI/SNF and INO80\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide nucleosome mapping plus KD with multiple chromatin remodeling complex dependencies identified; multiple orthogonal methods in a single study\",\n      \"pmids\": [\"23260146\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FOXA2 is required as a pioneer factor for chromatin opening and H3K4me1 deposition (enhancer priming) during human pancreatic specification; FOXA2 KO in hPSCs reduces pancreatic progenitor numbers and impairs GATA6 recruitment to pancreatic enhancers.\",\n      \"method\": \"CRISPR/Cas9 FOXA2 knockout in hPSCs; ATAC-seq; ChIP-seq for H3K4me1 and GATA6; directed pancreatic differentiation\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — CRISPR KO plus ATAC-seq and ChIP-seq in the same study; multiple orthogonal methods, single lab\",\n      \"pmids\": [\"31291575\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Pioneer factor Foxa2 binding site selection is directed by epigenetic priming (low levels of active chromatin marks in ESCs); Foxa2 binding alone is not sufficient for chromatin opening—increased accessibility requires synergistic co-binding with other endoderm transcription factors.\",\n      \"method\": \"ATAC-seq; ChIP-seq for active chromatin marks; ectopic Foxa2 expression in ESCs followed by genome-wide binding analysis\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genome-wide chromatin accessibility and binding studies with ectopic expression and endogenous conditions; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"31350899\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TET1 dioxygenase physically interacts with FOXA2 in endodermal lineage intermediates; TET depletion reduces FOXA2 binding at pancreatic progenitor enhancers; TET1-dependent DNA demethylation is required for FOXA2-associated chromatin remodeling during beta-cell differentiation.\",\n      \"method\": \"TET1/2/3 triple knockout hESCs; WGBS; ATAC-seq; ChIP-seq; co-immunoprecipitation of TET1 with FOXA2; directed beta-cell differentiation\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — co-IP identifying physical interaction, genome-wide methylome/accessibility analyses in KO context; multiple orthogonal methods, single lab\",\n      \"pmids\": [\"35798741\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Foxa1 and Foxa2 physically interact with the DNA-binding domain of the androgen receptor (AR); both Foxa proteins can be recruited to AR binding sites in the absence of Foxa consensus sequences, and AR is recruited to Foxa binding sites in the absence of an AR binding site, indicating mutual recruitment; Foxa2 (but not Foxa1) is expressed in the epididymis and binds the mE-RABP promoter.\",\n      \"method\": \"GST pull-down assay; gel-shift (EMSA); chromatin immunoprecipitation (ChIP); co-transfection reporter assays\",\n      \"journal\": \"Annals of the New York Academy of Sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — GST pulldown plus ChIP plus EMSA in one study; single lab, multiple methods\",\n      \"pmids\": [\"16467259\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Foxa1 and Foxa2 are required for normal bile duct development; in their absence, glucocorticoid receptor fails to bind the IL-6 promoter, causing enhanced IL-6 expression and cholangiocyte hyperproliferation; Foxa1/2 thus function as terminators of bile duct expansion by enabling GR-mediated repression of IL-6.\",\n      \"method\": \"Conditional double Foxa1/2 liver-specific knockout; ChIP for glucocorticoid receptor at IL-6 promoter; gene expression analysis\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with defined molecular mechanism (GR ChIP) plus IL-6 expression phenotype; single lab, multiple methods\",\n      \"pmids\": [\"19436110\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Foxa1/2 chromatin immunoprecipitation indicates that Nkx2.2 and tyrosine hydroxylase (TH) genes are direct targets in mesodiencephalic dopaminergic cells; Foxa1 and Foxa2 positively regulate Lmx1a and Lmx1b and inhibit Nkx2.2, and function cooperatively with Lmx1a/Lmx1b in a feedforward loop for DA neuron differentiation.\",\n      \"method\": \"Conditional Foxa1/2 knockout mice; chromatin immunoprecipitation for Foxa2 at Nkx2.2 and TH loci; gene expression analysis\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO combined with ChIP for direct targets; single lab\",\n      \"pmids\": [\"19607821\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Foxa2 directly binds Gli2 genomic regions (ChIP) and represses Gli2 transcription, thereby attenuating Shh signaling in ventral midbrain progenitors; Foxa1 and Foxa2 both positively and negatively regulate Shh pathway components to specify ventral midbrain progenitor identity.\",\n      \"method\": \"Conditional Foxa2 knockout in midbrain (Wnt1-Cre); gain-of-function studies; ChIP for Foxa2 at Gli2 locus; gene expression analysis\",\n      \"journal\": \"Mechanisms of development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirming direct Gli2 binding plus in vivo conditional KO/GOF; single lab\",\n      \"pmids\": [\"21093585\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Foxa2 acts as a co-activator of Nurr1-induced dopaminergic (DA) gene expression by displacing the Nurr1-CoREST repressor complex; in the presence of Foxa2, Nurr1 forms an activator complex with Foxa2 instead, reducing CoREST/Hdac1 enrichment at DA gene promoters and increasing H3 acetylation (open chromatin) at those promoters.\",\n      \"method\": \"Co-immunoprecipitation of Nurr1 with CoREST and Foxa2; ChIP for CoREST, Hdac1 and H3Ac at DA gene promoters; reporter assays; neural precursor cell differentiation\",\n      \"journal\": \"Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP defining complex composition, ChIP showing histone modification changes, promoter reporter assays; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"24496614\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"FOXA2 and HNF4α co-occupy thousands of genomic regulatory elements in hepatocytes; co-immunoprecipitation confirmed a physical interaction between HNF4α and GABP at transcription start sites, and HNF4α/FOXA2 frequently co-occupy distal elements together with USF2.\",\n      \"method\": \"ChIP-seq for FOXA2, HNF4α, and GABP; co-immunoprecipitation of HNF4α and GABP\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — ChIP-seq genome-wide binding plus co-IP; single lab, co-IP only for HNF4α-GABP interaction, not FOXA2 complex directly\",\n      \"pmids\": [\"19822575\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Foxa2 regulates polarity and epithelialization of endoderm cells; Foxa2-mutant endodermal cells fail to maintain apical-basal polarity and cannot establish proper cellular junctions, preventing integration into the endoderm epithelium, indicating Foxa2 promotes an epithelial fate and suppresses a mesenchymal fate.\",\n      \"method\": \"Foxa2 conditional knockout; immunohistochemistry for polarity/junction markers; time-lapse confocal imaging\",\n      \"journal\": \"Development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with live imaging and junction marker analysis; single lab, multiple methods\",\n      \"pmids\": [\"19234065\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Foxa1/2 deficiency in the liver abolishes the sexual dimorphism of hepatocellular carcinoma; Foxa1/2 are required for co-regulation of target genes by either ERα (in females) or the androgen receptor (AR) (in males) during hepatocarcinogenesis; FOXA2 binding site SNPs reduce co-occupancy of FOXA2 and ERα in human liver.\",\n      \"method\": \"Conditional double Foxa1/2 knockout after DEN-induced hepatocarcinogenesis; ChIP-seq for Foxa1/2, ERα, and AR; SNP analysis of FOXA2 binding sites\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with in vivo carcinogenesis model plus ChIP-seq for multiple TFs; multiple orthogonal methods, single lab\",\n      \"pmids\": [\"22265403\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"FOXA2 physically interacts with FXR (farnesoid X receptor/bile acid receptor) in hepatocytes; glucagon-activated FOXA2 inhibits FXR's ability to induce SHP (an anti-gluconeogenic nuclear receptor) through this protein-protein interaction; this represents a second arm of FXR regulation in fasting hepatic gluconeogenesis.\",\n      \"method\": \"In vitro protein-protein interaction assays (pull-down); cistromic (ChIP-seq) analysis; Foxa2 knockdown in primary hepatocytes; transactivation assays; site-directed mutagenesis of FXR\",\n      \"journal\": \"Journal of hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro binding assay plus ChIP and functional reporter assays; single lab\",\n      \"pmids\": [\"29981427\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Neurogenin3 (Neurog3) can autoactivate its own expression; Foxa2 cooperates synergistically with Neurogenin3 to amplify this autoregulation in vitro; Foxa2 colocalizes with Neurogenin3 in pancreatic progenitors in vivo; Foxa2 RNAi attenuates Neurogenin3-dependent activation of the endocrine developmental program.\",\n      \"method\": \"ChIP for Neurogenin3 at its own upstream region; reporter assays with Foxa2 co-expression; RNA interference of Foxa2 in mPAC cells; immunofluorescence co-localization in embryonic pancreas\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus reporter assays plus RNAi knockdown; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"23471965\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Foxa2 regulates hepatic gene networks in a physiological-state-dependent manner by interacting with different transcription factor partners depending on the presence or absence of cholic acid; distinct feedforward regulatory loops control Foxa2-dependent targets under different physiological conditions.\",\n      \"method\": \"Foxa2 liver-specific knockout; functional genomics (expression profiling under cholic acid diet); co-immunoprecipitation with partner transcription factors\",\n      \"journal\": \"Physiological genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — conditional KO plus expression profiling; co-IP evidence for partner interactions; single lab\",\n      \"pmids\": [\"19417011\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"β-catenin signaling directly regulates Foxa2 expression in uterine epithelia; Foxa2 knockdown in uterine epithelial cells causes defects in cell cycle regulation, suggesting a role for Foxa2 in controlling cell proliferation downstream of β-catenin.\",\n      \"method\": \"Conditional β-catenin ablation/activation in uterus; ChIP for β-catenin at Foxa2 locus; siRNA knockdown of Foxa2; cell cycle analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP establishing direct regulation plus KO/siRNA with functional readout; single lab\",\n      \"pmids\": [\"22945641\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"GATA6 and FOXA2 directly bind the Wnt6 promoter and cooperate to activate Wnt6 gene expression during extraembryonic endoderm formation, thereby activating the canonical WNT-β-catenin pathway.\",\n      \"method\": \"Chromatin immunoprecipitation; reporter assay with GATA6/FOXA2 overexpression; F9 teratocarcinoma cell differentiation model\",\n      \"journal\": \"Stem cells and development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirming direct promoter binding plus reporter assays; single lab\",\n      \"pmids\": [\"22607194\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FOXA2 controls distinct cis-regulatory networks in well- vs. poorly-differentiated pancreatic ductal adenocarcinoma cells via grade-specific partnerships with different co-binding transcription factors, despite being expressed in both cell types; FOXA2 genomic distribution and regulated gene programs differ extensively by differentiation grade.\",\n      \"method\": \"ChIP-seq for FOXA2 in multiple PDAC cell lines; ATAC-seq; transcriptome analysis; FOXA2 knockdown\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq and ATAC-seq across multiple cell lines with KD validation; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"31531882\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PHF8 histone demethylase transcriptionally upregulates FOXA2 by demethylating repressive histone marks on the FOXA2 promoter; PHF8 is required for neuroendocrine prostate cancer (NEPC) development and acts upstream of FOXA2 in the NEPC transcriptional program.\",\n      \"method\": \"PHF8 knockout in TRAMP mice; ChIP for repressive histone marks at FOXA2 promoter; gene expression analysis; xenograft models\",\n      \"journal\": \"The Journal of pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo KO model with ChIP-based mechanism; single lab\",\n      \"pmids\": [\"33009820\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FOXA2 drives prostate cancer adeno-to-neuroendocrine lineage transition; FOXA2 expression is induced by androgen deprivation; FOXA2 knockdown reverses the transition; FOXA2 directly regulates the KIT pathway, which is specifically activated in neuroendocrine prostate cancer.\",\n      \"method\": \"Single-cell multiomics (scRNA-seq + ATAC-seq) in genetically engineered mouse models; FOXA2 knockdown; KIT pathway inhibition experiments; human NEPC tumor analysis\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — single-cell multiomics plus KD rescue plus pharmacological inhibition; multiple orthogonal methods\",\n      \"pmids\": [\"36332622\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"FOXA2 acts as a pioneer factor that binds distinct classes of developmental enhancers in AR-independent prostate cancer subtypes in an LSD1-dependent manner; FOXA2 collaborates with JUN at chromatin to reprogram AP-1 transcriptional activity, driving cell state transitions to multiple cancer lineages.\",\n      \"method\": \"ChIP-seq for FOXA2 and JUN; ATAC-seq; LSD1 inhibition; FOXA2 overexpression in multiple PCa cell lines\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq and ATAC-seq establishing co-occupancy plus LSD1-dependence experiments; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"38851846\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In cardiomyocytes, FOXA2 directly represses RIPK3 gene transcription by binding its promoter region; loss of FOXA2 (through HDAC7-dependent suppression) increases RIPK3-dependent necroptosis; this pathway is governed by the CNEACR/HDAC7/Foxa2/RIPK3 axis.\",\n      \"method\": \"ChIP showing FOXA2 occupancy at RIPK3 promoter; FOXA2 overexpression/knockdown in cardiomyocytes; H/R injury model; HDAC7 nuclear/cytoplasmic fractionation\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP at RIPK3 promoter plus functional KD/OE assays; single lab\",\n      \"pmids\": [\"34588633\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TXNIP increases FoxA2 expression, which then binds the proximal FoxA2 site in the IAPP promoter to activate IAPP transcription; TXNIP also downregulates miR-124a, relieving miR-124a-mediated suppression of FoxA2; thus TXNIP controls IAPP expression via a TXNIP/miR-124a/FoxA2/IAPP cascade.\",\n      \"method\": \"Chromatin immunoprecipitation of FoxA2 at IAPP promoter; luciferase reporter assays; miR-124a overexpression/knockdown; beta-cell-specific Txnip knockout mice\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirming FoxA2 occupancy at IAPP promoter, miRNA manipulation, and in vivo KO; single lab\",\n      \"pmids\": [\"24627476\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Foxa2 binds specific DNA sequences in the cIAP1 promoter and activates cIAP1 transcription; Foxa2 overexpression decreases hepatocyte apoptosis while siRNA silencing increases it, suggesting Foxa2 modulates hepatic apoptosis through the cIAP1 pathway.\",\n      \"method\": \"EMSA and gel supershift assay; ChIP for Foxa2 at cIAP1 promoter; deletion reporter assays; siRNA knockdown; Foxa2 overexpression in HepG2 cells\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EMSA plus ChIP plus reporter deletion analysis confirm direct binding; single lab\",\n      \"pmids\": [\"23275033\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Hippo kinases Mst1/2 stabilize and phosphorylate Foxa2 in respiratory epithelial cells; Mst1/2 conditional knockout mice develop perinatal respiratory failure with defects in pneumocyte differentiation and surfactant protein expression attributed to reduced/destabilized Foxa2, independently of YAP.\",\n      \"method\": \"Mst1/2 conditional knockout mice; co-immunoprecipitation/phosphorylation assay of Foxa2 by Mst1/2; histological and molecular analysis of surfactant gene expression\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO phenotype plus biochemical demonstration of Foxa2 phosphorylation/stabilization by Mst1/2; single lab\",\n      \"pmids\": [\"23620511\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FOXA2 broadly controls gene expression programs in endometrial epithelial cells through modification of enhancer activity (not only direct promoter binding); simultaneous conditional inactivation of Foxa2 and Pten in endometrial epithelium causes lethal endometrial cancers with complete penetrance, establishing epistatic synergism between Foxa2 tumor suppressor and PI3K signaling.\",\n      \"method\": \"Conditional Foxa2 and Pten single/double knockout mice; RNA-seq; ChIP-seq (cistrome); organoid models; cell line functional assays\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis by conditional double KO in vivo plus cistrome analysis; multiple orthogonal methods, single lab\",\n      \"pmids\": [\"35703180\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"A de novo FOXA2 mutation (p.S169P) within the DNA-binding domain impairs FOXA2 transcriptional reporter activity and reduces protein levels, causing congenital hyperinsulinism and hypopituitarism with endoderm-derived organ abnormalities in humans.\",\n      \"method\": \"Whole-exome sequencing; transient transfection reporter assays in HEK293T cells with WT vs. mutant FOXA2; western blot for protein levels\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — functional validation of mutation in cell lines; single study, limited to transfection reporter\",\n      \"pmids\": [\"28973288\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Foxa2 expression in respiratory epithelial cells suppresses Th2 cell-mediated pulmonary inflammation; deletion of Foxa2 induces expression of IL-13, IL-4, eotaxins, Il33, and Ccl20, recruiting myeloid dendritic cells and Th2 cells; pulmonary inflammation was abrogated by anti-IL-4Rα antibody treatment.\",\n      \"method\": \"Respiratory epithelial cell-specific Foxa2 conditional knockout; cytokine/chemokine gene expression; flow cytometry for immune cell infiltrates; anti-IL-4Rα antibody rescue\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with defined cytokine program and antibody rescue; single lab, multiple methods\",\n      \"pmids\": [\"20483781\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Lhx1, Otx2, and Foxa2 form a protein complex with the chromatin-looping protein Ldb1 in anterior mesendoderm; this complex was characterized by proteomic co-immunoprecipitation and co-regulates development of anterior mesendoderm, node, and midline populations.\",\n      \"method\": \"Co-immunoprecipitation/proteomics; ChIP-seq for Lhx1, Otx2, Foxa2; conditional Lhx1 inactivation\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — proteomic co-IP identifying complex plus ChIP-seq; single lab\",\n      \"pmids\": [\"26494787\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TRIM36, an E3 ubiquitin ligase, directly interacts with FOXA2 and induces its K48-linked polyubiquitination, leading to FOXA2 proteasomal degradation; FOXA2 positively regulates NRF2 pathway activation and GPX4 levels in colorectal cancer cells to suppress ferroptosis.\",\n      \"method\": \"Co-immunoprecipitation of TRIM36 with FOXA2; ubiquitination assays (K48-linkage); FOXA2 depletion by siRNA/CRISPR; NRF2/GPX4 expression analysis\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus ubiquitination assay identifying writer/linkage; single lab\",\n      \"pmids\": [\"37875418\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"The Siah2 ubiquitin ligase controls HIF-1α availability; HIF-1α forms a transcriptional complex with FoxA2, and this complex drives expression of neuroendocrine prostate cancer target genes (Hes6, Sox9, Jmjd1a); this Siah2-HIF-1α/FoxA2 axis regulates neuroendocrine tumor formation.\",\n      \"method\": \"Co-immunoprecipitation of HIF-1α with FoxA2; gene expression analysis; Siah2 inhibition experiments (review/perspective summarizing experimental findings from cited primary work)\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — review/perspective summarizing co-IP data from primary studies; not a primary experimental paper\",\n      \"pmids\": [\"21037926\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Foxa1 and Foxa2 control glucagon gene expression through the G2 element in pancreatic alpha cells; Foxa2 (but not Foxa1) regulates MafB, Pou3f4, Pcsk2, Nkx2.2, Kir6.2, and Sur1 gene expression; combined Foxa1/Foxa2 loss affects glucagon secretion; Foxa2 directly binds the promoters of Nkx2.2, Kir6.2, Sur1, Gipr, Isl1, and Pou3f4 genes.\",\n      \"method\": \"siRNA knockdown of Foxa1/Foxa2 in primary rat alpha cells and alpha-cell lines; ChIP for Foxa2 at target gene promoters; glucagon secretion assays\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirming direct binding at multiple promoters plus siRNA functional assays; single lab\",\n      \"pmids\": [\"25057789\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FOXA2 (HNF3B) is a winged-helix pioneer transcription factor whose nuclear activity is regulated by multiple post-translational modifications—including insulin/PI3K/Akt-mediated phosphorylation at Thr156 causing cytoplasmic sequestration, glucagon-induced p300-mediated acetylation at Lys259 promoting activity, SIRT1-mediated deacetylation targeting it for proteasomal degradation, SUMO-1 modification at Lys6 stabilizing it, IKKα-mediated phosphorylation at Ser107/Ser111 suppressing transactivation, and TRIM36-mediated K48-polyubiquitination causing degradation; in the liver it acts as a chromatin-level co-activator that enables CREB and glucocorticoid receptor recruitment to gluconeogenic gene promoters during fasting, activates fatty acid oxidation and ketogenesis programs, and cooperates with nuclear receptors (FXR, GR) and partner transcription factors (HNF4α, GATA6); in the pancreas it functions as a pioneer factor required for enhancer priming (H3K4me1 deposition), chromatin opening, and recruitment of GATA6 and other lineage TFs, directly activating Kir6.2, SUR1, Hadhsc, ChREBP, and Pdx1 to control insulin secretion and beta-cell identity; in the brain it cooperates with Nurr1 by displacing the Nurr1-CoREST-HDAC1 repressor complex to drive dopaminergic gene expression; and its crystal structure reveals that DNA recognition occurs primarily through helix H3 and wing 1 of the canonical winged-helix fold.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"FOXA2 (HNF3B) is a winged-helix pioneer transcription factor that opens chromatin at developmental and metabolic enhancers and licenses other transcription factors for DNA binding, thereby controlling endoderm-derived lineage specification and tissue-specific gene programs [#13, #12]. Its DNA-binding domain engages the forkhead consensus (GTAAACA) through helix H3 and wing 1 of the canonical winged-helix fold, with wing 2 required for optimal binding [#11]. As a pioneer factor it cooperates with the histone variant H2A.Z and Nap1l1-coupled SWI/SNF and INO80 remodelers to deplete nucleosomes at endodermal loci, and during human pancreatic specification it deposits H3K4me1 at enhancers and enables GATA6 recruitment; its binding-site selection is guided by epigenetic priming and TET1-dependent DNA demethylation, and accessibility gains require synergistic co-binding with partner endoderm factors [#12, #13, #14, #15]. In the pancreas FOXA2 is required for beta-cell identity and glucose-stimulated insulin secretion, directly activating Kir6.2, SUR1, Hadhsc, and ChREBP and cooperating with Insm1, Neurod1, and Neurogenin3 [#7, #8, #9, #10, #25]. In the liver it acts as a chromatin-level co-activator that enables CREB and glucocorticoid-receptor recruitment to gluconeogenic promoters during fasting and drives fatty-acid oxidation and ketogenesis, cooperating with HNF4\\u03b1 and the bile-acid receptor FXR [#1, #21, #24]. In the brain it converts the Nurr1-CoREST-HDAC1 repressor complex into an activator complex to drive dopaminergic gene expression [#20]. FOXA2 nuclear activity and stability are tuned by an extensive set of post-translational modifications: insulin/PI3K/Akt phosphorylation at Thr156 drives cytoplasmic sequestration, glucagon-induced p300 acetylation at Lys259 activates it while SIRT1 deacetylation targets it for proteasomal degradation, SUMO-1 modification at Lys6 stabilizes it, IKK\\u03b1 phosphorylation at Ser107/Ser111 suppresses transactivation, and TRIM36-mediated K48-polyubiquitination drives its degradation [#0, #2, #3, #6, #5, #41]. It also operates as a context-dependent tumor suppressor or lineage-reprogramming driver, synergizing epistatically with PI3K/PTEN signaling in endometrium and driving AR-independent adeno-to-neuroendocrine transitions in prostate cancer via JUN/LSD1-dependent enhancer reprogramming [#37, #31, #32]. A de novo p.S169P mutation in the DNA-binding domain causes congenital hyperinsulinism and hypopituitarism with endoderm-organ abnormalities [#38].\",\n  \"teleology\": [\n    {\n      \"year\": 2004,\n      \"claim\": \"Established that insulin signaling inactivates FOXA2 not by altering its expression but by spatial regulation, defining a phosphorylation-controlled nucleocytoplasmic switch over its metabolic program.\",\n      \"evidence\": \"Adenoviral Foxa2T156A phospho-mutant expression with nuclear/cytoplasmic fractionation in insulin-resistant mice\",\n      \"pmids\": [\"15616563\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the precise Akt-FOXA2 cytoplasmic-retention machinery not resolved\", \"Does not address PTM crosstalk with later-discovered acetylation/sumoylation\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Showed FOXA2 is required for beta-cell secretory competence by directly controlling K-ATP channel subunits and a metabolic target, linking the factor to insulin-secretion physiology.\",\n      \"evidence\": \"Beta-cell-specific conditional Foxa2 knockout with islet functional assays, ChIP, and reporter assays on Hadhsc\",\n      \"pmids\": [\"15314688\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs. indirect regulation of Kir6.2/SUR1 not fully separated\", \"Pioneer-factor role at these loci not yet defined\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Defined FOXA2 as a chromatin-level co-activator that integrates cAMP and glucocorticoid signals by enabling CREB and GR occupancy at gluconeogenic promoters during fasting.\",\n      \"evidence\": \"Hepatocyte conditional Foxa2 ablation with ChIP for CREB and GR at gluconeogenic promoters\",\n      \"pmids\": [\"16098831\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether FOXA2 directly opens chromatin or recruits co-factors not mechanistically separated here\", \"Stoichiometry of FOXA2/CREB/GR complex unknown\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Demonstrated mutual recruitment between FOXA2 and the androgen receptor, an early indication that FOXA proteins direct nuclear-receptor cistromes.\",\n      \"evidence\": \"GST pull-down, EMSA, ChIP, and reporter assays; epididymis mE-RABP promoter\",\n      \"pmids\": [\"16467259\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of FOXA2-AR DBD interaction not resolved\", \"Genome-wide generality not established in this study\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Extended FOXA2 partnerships to hepatic master regulators, showing genome-wide co-occupancy with HNF4\\u03b1 at thousands of regulatory elements.\",\n      \"evidence\": \"ChIP-seq for FOXA2, HNF4\\u03b1, GABP plus co-IP\",\n      \"pmids\": [\"19822575\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct FOXA2-HNF4\\u03b1 physical interaction not demonstrated by reciprocal co-IP\", \"Functional consequence of co-occupancy not tested by perturbation\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined FOXA1/2 as developmental terminators of bile-duct expansion through enabling GR-mediated repression of IL-6.\",\n      \"evidence\": \"Liver-specific Foxa1/2 double conditional KO with GR ChIP at IL-6 promoter\",\n      \"pmids\": [\"19436110\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct FOXA-GR interaction at IL-6 not biochemically shown\", \"Redundancy between FOXA1 and FOXA2 not separated\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Placed FOXA1/2 in midbrain dopaminergic specification as direct regulators of TH, Nkx2.2, and Shh-pathway feedforward loops.\",\n      \"evidence\": \"Conditional Foxa1/2 KO with ChIP for Foxa2 at Nkx2.2/TH and Gli2 loci\",\n      \"pmids\": [\"19607821\", \"21093585\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs. indirect repression of Gli2/Nkx2.2 not fully dissected\", \"Co-factor requirements for repression unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Revealed FOXA2 controls endoderm epithelialization and polarity, linking the factor to morphogenesis beyond gene transcription.\",\n      \"evidence\": \"Foxa2 conditional KO with polarity/junction immunostaining and time-lapse imaging\",\n      \"pmids\": [\"19234065\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Transcriptional targets driving polarity not identified\", \"Cell-autonomy not fully resolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identified a kinase that suppresses FOXA2 transactivation, connecting inflammatory TNF\\u03b1/IKK\\u03b1 signaling to the FOXA2/NUMB/NOTCH1 axis in liver cancer.\",\n      \"evidence\": \"IKK\\u03b1-FOXA2 co-IP, phospho-Ser107/111 detection, transactivation reporters, knockdown and tumor analysis\",\n      \"pmids\": [\"22196886\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct kinase-substrate phosphorylation in vitro not the sole readout\", \"Effect on FOXA2 DNA binding vs. co-factor recruitment not separated\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Defined the pioneer mechanism: FOXA2 with H2A.Z drives nucleosome depletion at endodermal loci via Nap1l1-coupled SWI/SNF and INO80, with DNA methylation opposing accessibility.\",\n      \"evidence\": \"MNase-seq, ChIP-seq, Foxa2 knockdown during ESC-to-endoderm differentiation, remodeler inhibition\",\n      \"pmids\": [\"23260146\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct FOXA2-remodeler contacts not biochemically defined\", \"Order of H2A.Z deposition vs. FOXA2 binding unresolved\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Showed FOXA2 stability is positively controlled by SUMO-1 modification at Lys6, adding a degradation-protective PTM layer.\",\n      \"evidence\": \"K6R mutagenesis, SUMO-1 fusion rescue, UBC9 knockdown, PIAS1 co-IP, reporter assays across cell lines\",\n      \"pmids\": [\"23118920\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological signal driving sumoylation not identified\", \"Crosstalk with ubiquitination machinery not mapped\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Established glucagon-induced Lys259 acetylation as a positive activity switch with p300 as writer and SIRT1 as eraser, opposing the insulin-driven inhibition.\",\n      \"evidence\": \"K259Q/K259R mutagenesis, HDAC inhibition, p300/SirT1 co-IP, adenoviral in vivo expression\",\n      \"pmids\": [\"23416070\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How acetylation alters FOXA2 chromatin engagement not resolved\", \"Integration with Thr156 phosphorylation not mechanistically linked\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Clarified SIRT1 as a nutrient-responsive regulator that deacetylates FOXA2 and targets it for proteasomal turnover, coupling fasting signals to FOXA2 stability.\",\n      \"evidence\": \"LC-MS/MS acetyl-site mapping, SIRT1-FOXA2 co-IP, reporter assays, murine starvation model\",\n      \"pmids\": [\"24875183\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ligase coupling SIRT1 deacetylation to degradation not identified here\", \"Apparent context-dependence vs. SIRT1's positive role on Pdx1 unresolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Showed SIRT1-FOXA2 cooperation can also be activating, forming a complex on the Pdx1 promoter required for islet development.\",\n      \"evidence\": \"Co-IP, ChIP on Pdx1 promoter, pancreas-specific Sirt1 KO mice\",\n      \"pmids\": [\"24163589\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Reconciliation with SIRT1-driven FOXA2 degradation elsewhere not addressed\", \"Direct vs. indirect Pdx1 effect not fully separated\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Provided the structural basis of FOXA2 DNA recognition, localizing specificity to helix H3 and wing 1 and showing wing 2 contributes to affinity.\",\n      \"evidence\": \"2.8 \\u00c5 co-crystal of FOXA2 DBD with consensus DNA and ITC for wing 2 deletion\",\n      \"pmids\": [\"28644006\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of full-length factor or nucleosome-bound complex not solved\", \"Basis of pioneer activity not captured by naked-DNA structure\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Linked FOXA2 directly to human Mendelian disease through a DNA-binding-domain mutation impairing transactivation and protein stability.\",\n      \"evidence\": \"Whole-exome sequencing of patients; WT vs. p.S169P reporter and western blot in HEK293T\",\n      \"pmids\": [\"28973288\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional validation limited to transient transfection reporters\", \"In vivo recapitulation of patient phenotype not shown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstrated FOXA2 is the pioneer factor priming pancreatic enhancers (H3K4me1) and enabling GATA6 recruitment during human pancreatic specification.\",\n      \"evidence\": \"CRISPR FOXA2 KO in hPSCs with ATAC-seq, H3K4me1/GATA6 ChIP-seq, directed differentiation\",\n      \"pmids\": [\"31291575\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct FOXA2-GATA6 interaction not biochemically tested\", \"Mechanism of H3K4me1 deposition (which methyltransferase) unresolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Refined the pioneer model: epigenetic priming directs FOXA2 site selection and binding alone is insufficient for opening, which requires synergistic co-binding factors.\",\n      \"evidence\": \"ATAC-seq, ChIP-seq for active marks, ectopic Foxa2 expression in ESCs with genome-wide binding\",\n      \"pmids\": [\"31350899\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of all required co-binding partners not enumerated\", \"Quantitative threshold for productive opening not defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Connected DNA demethylation to FOXA2 pioneering, showing TET1 physically interacts with FOXA2 and is required for its binding at pancreatic enhancers.\",\n      \"evidence\": \"TET triple-KO hESCs, WGBS, ATAC-seq, ChIP-seq, TET1-FOXA2 co-IP, beta-cell differentiation\",\n      \"pmids\": [\"35798741\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether FOXA2 recruits TET1 or vice versa not resolved\", \"Direct demethylation at FOXA2 sites vs. global effects not separated\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Revealed a repressive FOXA2 role in mature beta cells, where its loss enlarges the docked granule pool and enhances first-phase secretion via trafficking genes.\",\n      \"evidence\": \"Inducible Pdx1-CreERT2 Foxa2 ablation with EM, Ca2+/cAMP measurement, expression profiling\",\n      \"pmids\": [\"17908556\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct trafficking-gene targets not all mapped\", \"Reconciliation with FOXA2's earlier activating role not addressed\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Showed FOXA1/FOXA2 redundancy and a direct ChREBP target underlying beta-cell glucose homeostasis.\",\n      \"evidence\": \"Inducible double conditional KO, islet secretion and Ca2+ assays, ChIP at ChREBP promoter\",\n      \"pmids\": [\"20534694\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Degree of FOXA1/2 functional non-equivalence not quantified\", \"Downstream metabolic consequences of ChREBP loss not fully traced\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identified FOXA1/2 control of glucagon-gene expression and an alpha-cell-specific FOXA2 target set, extending its role across both islet endocrine lineages.\",\n      \"evidence\": \"siRNA knockdown in alpha cells, ChIP at multiple promoters, glucagon secretion assays\",\n      \"pmids\": [\"25057789\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of FOXA2-specific (vs FOXA1) target selectivity unknown\", \"In vivo alpha-cell phenotype not tested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Placed FOXA2 within a TXNIP/miR-124a regulatory cascade controlling IAPP transcription in beta cells.\",\n      \"evidence\": \"ChIP at IAPP promoter, luciferase assays, miR-124a manipulation, beta-cell Txnip KO mice\",\n      \"pmids\": [\"24627476\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct FOXA2 regulation by miR-124a vs. indirect not fully separated\", \"Relevance to amyloid pathology not established\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Defined a neuronal co-activator mechanism: FOXA2 converts the Nurr1-CoREST-HDAC1 repressor into an activator complex, opening dopaminergic gene chromatin.\",\n      \"evidence\": \"Nurr1/CoREST/Foxa2 co-IP, ChIP for CoREST/Hdac1/H3Ac, reporters, neural precursor differentiation\",\n      \"pmids\": [\"24496614\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of complex switching not resolved\", \"Generality beyond dopaminergic promoters not tested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified combinatorial maturation circuitry in beta cells, with Insm1, Neurod1, and FOXA2 physically interacting and co-occupying maturity genes.\",\n      \"evidence\": \"Co-IP, ChIP-seq for all three factors, Insm1 conditional KO, expression profiling\",\n      \"pmids\": [\"25828096\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Order of complex assembly on chromatin not resolved\", \"Pairwise vs. ternary binding requirements not dissected\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Placed FOXA2 in an anterior-mesendoderm developmental complex with Lhx1, Otx2, and the chromatin-looper Ldb1.\",\n      \"evidence\": \"Proteomic co-IP and ChIP-seq for Lhx1/Otx2/Foxa2, conditional Lhx1 inactivation\",\n      \"pmids\": [\"26494787\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct binary FOXA2 contacts within the complex not mapped\", \"Functional requirement of FOXA2 within Ldb1 looping not isolated\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Added a non-genomic arm of hepatic gluconeogenic control, with glucagon-activated FOXA2 physically inhibiting FXR-mediated SHP induction.\",\n      \"evidence\": \"Pull-down, ChIP-seq, Foxa2 knockdown in primary hepatocytes, transactivation assays, FXR mutagenesis\",\n      \"pmids\": [\"29981427\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Interaction surface on FOXA2 not mapped\", \"In vivo contribution to fasting glycemia not quantified\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established FOXA2 as a tumor suppressor that synergizes epistatically with PI3K/PTEN, acting through enhancer modification in endometrial epithelium.\",\n      \"evidence\": \"Conditional Foxa2/Pten single and double KO mice, RNA-seq, ChIP-seq, organoids, cell assays\",\n      \"pmids\": [\"35703180\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanistic link between FOXA2 loss and PI3K hyperactivation not fully defined\", \"Key suppressed enhancer targets not pinpointed\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed FOXA2 cistrome and regulated programs are grade-specific in pancreatic cancer, set by differential co-binding partners despite constant expression.\",\n      \"evidence\": \"ChIP-seq and ATAC-seq across PDAC lines with knockdown validation\",\n      \"pmids\": [\"31531882\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of grade-specific partner factors not fully resolved\", \"Drivers of differential FOXA2 recruitment unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified upstream epigenetic activation of FOXA2 by PHF8 in neuroendocrine prostate cancer.\",\n      \"evidence\": \"PHF8 KO in TRAMP mice, ChIP for repressive marks at FOXA2 promoter, xenografts\",\n      \"pmids\": [\"33009820\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct PHF8 demethylation at FOXA2 promoter vs. indirect not separated\", \"Generality across NEPC models not tested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established FOXA2 as a driver of prostate adeno-to-neuroendocrine lineage transition induced by androgen deprivation, acting through the KIT pathway.\",\n      \"evidence\": \"Single-cell multiomics in GEMMs, FOXA2 knockdown rescue, KIT inhibition, human NEPC analysis\",\n      \"pmids\": [\"36332622\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs. indirect KIT regulation not fully separated\", \"Initiating trigger of FOXA2 induction not defined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defined the mechanism of FOXA2 lineage reprogramming in AR-independent prostate cancer through LSD1-dependent enhancer binding and JUN/AP-1 collaboration.\",\n      \"evidence\": \"FOXA2/JUN ChIP-seq, ATAC-seq, LSD1 inhibition, FOXA2 overexpression in PCa lines\",\n      \"pmids\": [\"38851846\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct FOXA2-LSD1 and FOXA2-JUN physical contacts not biochemically mapped\", \"Reversibility of reprogrammed states not tested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Added a degradation pathway: the E3 ligase TRIM36 drives K48-polyubiquitination and proteasomal turnover of FOXA2, linking FOXA2 levels to ferroptosis control via NRF2/GPX4.\",\n      \"evidence\": \"TRIM36-FOXA2 co-IP, K48 ubiquitination assays, FOXA2 depletion, NRF2/GPX4 analysis in colorectal cells\",\n      \"pmids\": [\"37875418\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ubiquitination acceptor lysines on FOXA2 not mapped\", \"Direct vs. indirect NRF2/GPX4 regulation not separated\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified a cardioprotective transcriptional-repressor role, with FOXA2 directly silencing RIPK3 to limit necroptosis via the CNEACR/HDAC7/Foxa2 axis.\",\n      \"evidence\": \"ChIP at RIPK3 promoter, FOXA2 OE/KD in cardiomyocytes, H/R injury model, HDAC7 fractionation\",\n      \"pmids\": [\"34588633\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct repression mechanism (co-repressor recruitment) not defined\", \"Generality to in vivo ischemia not fully established\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Linked FOXA2 to immune homeostasis, showing respiratory-epithelial FOXA2 suppresses Th2 inflammation via a defined cytokine/chemokine program.\",\n      \"evidence\": \"Respiratory-epithelium Foxa2 conditional KO with cytokine profiling, flow cytometry, anti-IL-4R\\u03b1 rescue\",\n      \"pmids\": [\"20483781\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct FOXA2 cytokine-gene targets not all defined\", \"Whether repression is direct or indirect unresolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Showed FOXA2 stability is regulated by Hippo kinases Mst1/2 in lung, required for pneumocyte differentiation and surfactant expression, independent of YAP.\",\n      \"evidence\": \"Mst1/2 conditional KO mice, Foxa2 phosphorylation/co-IP assays, surfactant gene analysis\",\n      \"pmids\": [\"23620511\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Phosphosite(s) mediating Mst1/2 stabilization not mapped\", \"Mechanism of stabilization (degradation block) unresolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how the diverse PTM inputs (Thr156 phosphorylation, Lys259 acetylation, Lys6 sumoylation, Ser107/111 phosphorylation, K48 ubiquitination) are integrated into a single quantitative control of FOXA2 activity, and what structural basis allows the same factor to act as activator, repressor, tumor suppressor, and lineage-reprogramming oncogenic driver across tissues.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structure of FOXA2 engaging a nucleosome to explain pioneer activity\", \"No unified model reconciling context-dependent activating vs. repressive and tumor-suppressive vs. oncogenic roles\", \"Direct physical contacts to most named co-factors not biochemically mapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [11, 7, 35]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [1, 13, 20, 29]},\n      {\"term_id\": \"GO:0140097\", \"supporting_discovery_ids\": [12, 13]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 6]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [13, 12]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [1, 13, 20]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [13, 18, 22, 40]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [12, 13, 14, 15]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 1, 2, 7]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [31, 32, 37, 23]}\n    ],\n    \"complexes\": [\n      \"Insm1-Neurod1-FOXA2 beta-cell maturity complex\",\n      \"Lhx1-Otx2-FOXA2-Ldb1 anterior mesendoderm complex\",\n      \"Nurr1-FOXA2 dopaminergic activator complex\"\n    ],\n    \"partners\": [\n      \"GATA6\",\n      \"HNF4A\",\n      \"FXR\",\n      \"SIRT1\",\n      \"Nurr1\",\n      \"Insm1\",\n      \"JUN\",\n      \"TET1\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":9,"faith_pct":88.88888888888889}}